Authors note: This is not MY personal story, per se, (despite the my pandemic pregnancy headline), but a story told by our readers, week by week. Todays is shared by Hillary, from The Woodlands, Texas.

You might have heard that being pregnant, trying to get pregnant, or delivering right about now is strange, in this age of coronavirus. But how? In what ways? Were going to tell you. To contribute your own experience, scroll all the way down to the bottom of this article and tap the link.

When Hillary Calhouns fertility doctor brought her in for a procedure and then a nurse called her just a few short days later, asking her to come into the office immediately, the now-36-year-old had a hunch something wasnt right.

Hillarys husband, Bobby Calhoun, was out of town for work, so he couldnt accompany her to the appointment, but Hillary headed to the Houston-area clinic anyway, holding her breath a little, so to speak. The couple had been trying to get pregnant for years. Bobby had even gone under the knife as doctors reversed his vasectomy, which happened about 3 to four years ago, Hillary said in a phone call last week.

But back to Hillarys appointment. It was April 2019, and Hillary was in the office to learn about the results from her procedure. The previous Friday, doctors had performed a hysteroscopy, which is when they take a look at the uterus. A camera, of sorts, goes up the cervix, and specialists can then examine the fallopian tubes, ovaries and womb. Hillary waited and waited for the bottom line.

(The doctor) kept using the word abnormalities -- and he went on and on without really saying it, Hillary said.

After battling infertility for years, Hillary was aching to know what it was.

Then the doctor showed her the test results on a computer, and Hillary spotted the word carcinoma. Shes had family members whove experienced cancer, so she was familiar with some of the terminology. She knew that word.

Finally, Hillary said something to the effect of, OK, so I have cancer?

The doctor confirmed: That appeared to be the case. He told Hillary he thought the cancer looked to be in its early stages, but she would have to go through some more tests. The cancer, Hillary learned, was endometrial.

It was like, within one moment, someone took my dream away to have a baby, Hillary recalls thinking.

As soon as she could, she called Bobby, who was still in North Carolina on business, and she broke the news to him over the phone. Bobby was up on a roof at the time, and he got down and sped to the airport to be by Hillarys side.

The couple has been married about seven years. Bobby is a wonderful husband, Hillary said. He was incredibly supportive through this stressful time.

Hillary then made an appointment with a gynecological oncologist, who confirmed the cancer, ordered more tests and recommended a hysterectomy. The doctor said she believed this was a serious and life-threatening situation. A hysterectomy is an operation to remove a womans uterus entirely. But Hillary wanted to pause before making any major decisions.

Now, Im not trying to be reckless with my own life, but I thought it was early, said Hillary, adding that the doctor did confirm that the cancer appeared to be stage one.

I wanted to preserve my fertility, Hillary said.

While Bobby has four children (who are now a little older) from a previous marriage, Hillary still dreamed of becoming a mother. So she examined her options and asked about the possibility of hormone therapy. Her doctor agreed -- she could give it a shot.

Six months after starting, Hillary was cancer-free. It worked.

And then in October 2019, she went straight from cancer treatment to in vitro fertilization. It was a whirlwind.

Before they knew it, January arrived, and the couple learned they were pregnant. It worked.

It was unbelievable news, Hillary said.

To rewind a bit, the Calhouns werent always sure a baby would be possible.

Between Bobbys vasectomy and Hillarys history of endometriosis, polycystic ovary syndrome and uterine fibroids, she said, she had been told by doctors over the years that pregnancy might not be in the cards for her.

Shed tried the infertility drug Clomid to no avail.

And at some point, she started to fear that the doctors might be right.

I thought Id have to kiss that (pregnancy) dream goodbye, Hillary said.

But the couple thought it was worth it to fully explore the possibility. It was Bobby, after all, who was inspired and motivated to go for it.

I just kept thinking, if Gods going to put it on my husbands heart, there has to be a reason, Hillary said.

Cancer, Hillary said, turned out to be a blessing in disguise.

She had been experiencing some unexplained health issues, and her yearly or bi-yearly exams werent showing anything out of the ordinary.

But a Pap smear only tests for cervical cancer, not uterine cancer, Hillary said.

If I hadnt had infertility, I wouldnt have known, she told us. It was better than being diagnosed later, like when I had an infant. It happened exactly how it was supposed to, and this is how it was supposed to be.

Hillary has clarity and confidence about this. You can hear it in her voice. Shes also incredibly warm, chatty, open and ready for this miracle baby.

By waking up every morning and being grateful for the small things, it keeps you from getting frustrated from not being able to do all the things were used to doing, she said.

And thats not to say the ongoing pandemic has been easy on the couple.

Hillary was a few months into her pregnancy when COVID-19 hit. She and Bobby agreed: With so many unknowns, shed essentially go on lockdown mode. It seemed to be the safest option. Luckily, Hillary was able to work from home, for the most part.

Its just one of those things where you adapt because you have to, Hillary said. You survive because you have to. You cant let the fear consume you.

Still, she didnt shy away from addressing the sad parts. It feels strange that Bobby hasnt even met her doctor. Their doula, as it stands now, wont be able to attend the birth.

The couple even went through a bit of a scare at 20 weeks -- a bad bleed, as Hillary describes it -- and she had to take an ambulance to the emergency room.

Policies at their medical facility were strict. At first, hospital officials wouldnt even let Bobby in the door. Although he was eventually permitted into labor and delivery, where doctors were treating Hillary, he was told he couldnt leave the couples room -- not even to get a Coke, Hillary said.

The baby, by the way, is a girl. She and Hillary are doing just fine these days, despite a hot Texas summer. Olivia Grace is due Oct. 2. Her name has been picked out for a while now. Its almost like shes here already, the way Hillary talks about her and refers to her so effortlessly as Olivia. This is the little girl she was destined to have.

As far as labor and delivery are concerned, the plan for now is to labor at home with the doula for as long as possible. When Hillary arrives at the hospital, shes told shell have to wear a mask throughout labor. It sounds hard, but shes been rolling with the punches.

Ive had to learn to be a lot more open, Hillary said. With coronavirus, its easy to let fear consume you. And that could affect the delivery. So I want to avoid that as much as possible. I (have to) just go with the flow.

For a couple who doubted at some point that theyd ever get to this stage of life, it sounds like theyre doing a lot of stopping, taking in their surroundings and appreciating the beauty all around them.

(This surreal time) is a lot more intentional than normal life, which can be like, go go go go! Hillary said. To slow down has been really healthy for my pregnancy. Olivia was meant to be born in this time. There was a reason for it. Ill find out someday.

Go here to see the original:
My pandemic pregnancy: From infertility to cancer to IVF to a 20-week scare: It happened exactly how it was supposed to' - KPRC Click2Houston

Recommendation and review posted by Bethany Smith

GIRLS Aloud singer Sarah Harding revealed this week that she has advanced breast cancer at the age of just 38.

Her shocking diagnosis led to an outpouring of support from fans and stars, including former bandmates Cheryl, 37, Nadine Coyle, 35, Kimberley Walsh, 38, and Nicola Roberts, 34.

14

Sarah shared her diagnosis on social media, saying she is doing her best to keep positive.

And she has good reason. Three women who were once given the exact same news as Sarah have told us how they have carried on living.

They have also backed our Get Checked breast cancer campaign and urged women - of any age - who are worried they may have the disease to see their doctors.

Here, they reveal the battles they faced and overcame.

FORMER city worker Louisa Rasmussen was diagnosed with incurable breast cancer at 34 - but says she is "living with" the disease and believes Sarah can do the same.

A year after Louisa gave up a high-flying, stressful career to become a yoga teacher she discovered she had incurable breast cancer and eight secondary tumours in her liver.

14

Today Louisa, now 38, who lives with boyfriend James Ralph, 37, in London runs Breathe, Balance, Be - which helps other cancer victims to meditate.

In 2013 Louisa found a lump on her left breast and after a biopsy it was found to be benign.

But then in 2017 a second lump appeared this time on her right side - but she didnt get it checked for nine months.

She said: I put it down to monthly changes in my cycle initially. I have no idea why I waited that long. A part of me was scared.

14

A biopsy confirmed it was oestrogen positive breast cancer. Then a full body scan to start planning treatments confirmed I had multiple metastases in my liver.

There were eight tumours in all incurable secondary breast cancer.

Being told was like an out of body experience. I had a sense of disbelief, shock. I needed six cycles of combination chemotherapy.

I was hoping I might be able to have my eggs frozen but because it has already spread they wanted to get me on treatment asap.

14

Its a hell of a lot to take in. You are still processing and grieving for that years on.

During treatment I wore the cold cap which I hated. I lost 70 percent of my hair but it was awful when it came out in the shower in clumps.

Your life stops and there were days I was too ill to get up. Its tough.

The weekend after my chemotherapy finished I trained as a Yoga Nidra teacher and started breath work so I could guide others into relaxation and better breathing which I think helps when you have cancer.

14

I have never asked for my prognosis and I dont want to know.

I feel very good and very bloody lucky. Im living with secondary, incurable breast cancer. And living is key.

So is early detection. I did have some 'what ifs?' after what happened to me. I used to ask myself what if it was caught earlier, why did I wait so long?

But my message is simple: dont be scared, take control, it could be nothing, but you must get checked.

BTW

CATHERINE Priestley, Clinical Nurse Specialist at Breast Cancer Now said: Secondary breast cancer - also referred to as advanced, metastatic or stage four - is when breast cancer cells spread from the breast to other parts of the body, most commonly the liver, lungs, bones, or brain. At this point, while it can be treated and managed, it is no longer curable.

The aim of treatment is to control the cancer, relieve any symptoms, and maintain health, wellbeing, and a good quality of life for as long as possible. Treatment can include chemotherapy, hormone therapies and targeted therapies.

Everyones diagnosis is different, but what we do know is that as treatments have improved, more and more people are living longer after a secondary breast cancer diagnosis.

"Accessing the right support and treatment can help the thousands of people living with the disease in the UK continue normal life as much as possible so we must ensure that everyone gets the care they need."

EMMA Gittens is 40, separated, and lives in Hereford with her sons Noah, nine, and Freddie, seven. She was diagnosed with triple-negative breast cancer in October 2017, at the age of 37.

In September last year, doctors discovered it had spread to her pancreas and she was told it was incurable.

14

She says she sees her condition as a "chronic illness rather than a death sentence".

Emma, an HR administrator, said: It was such a shock when I was diagnosed.

I never expected to have cancer at such a young age. After I found the tumour in my right breast I had chemotherapy and surgery and doctors said that it hadnt spread.

But then in September last year they found that it had, to my pancreas and ovaries and at that stage it was diagnosed as incurable.

14

Id had a thickening of the breast tissue which was quite painful for about 12 months before I was diagnosed. I went to see the GP but they said it was hormonal and not to worry.

"Then when a lump eventually appeared a year later, I went back to the GP and was referred to the breast clinic straight away.

"I wish Id pushed for more investigations at the time that I had the pain - I dont know if it was linked, but if it had been looked into it could have been caught earlier and made a difference to me.

I fully back the Sun on Sunday's campaign - I think getting to the doctors and getting checked out straight away is so important.

I never expected to have cancer at such a young age.

"I have two sons and I just make the most of every minute with them. During lockdown they have been at home with me for six months, and weve done loads of things together which has been lovely.

"I have weekly chemotherapy now at the hospital and its keeping me stable. I feel really healthy - I go to spinning classes at the gym once a week. I see it as a chronic illness rather than a death sentence.

14

"When I was first diagnosed I found that talking to other women my age who had breast cancer too really helped me get through it.

"It saved me from plunging into deep despair at having such a life threatening illness, and thats what Sarah should do too.

"If Sarah has lots of support like I did, from other women who understand what she is going through, then she will get through it too.

"She needs not to treat it like a death sentence - like I dont - and just take each day at a time.

14

Book a GP check

WOMEN who fear they may have breast cancer must book a GP appointment, a health minister has said.

Jo Churchill, who beat the disease twice, said seeing your doctor as soon as possible will mean a better chance of survival.

Ms Churchill said: I heard Sarah Harding bravely sharing the difficult news about the progress of her cancer this week and I wish her the very best with her treatment.

As someone who has had breast cancer twice, I cannot stress enough the importance of going to see your GP.

Catching any cancer early means a higher chance of successful treatment.

Ms Churchill is supporting our campaign Get Checked for women to get their breasts looked at early.

It is backed by Breast Cancer Now and CoppaFeel! as we ask women to see their GPs if they notice anything suspect.

ZEENAT Khanam is married to husband Ash, 40, and lives in Oldham, Greater Manchester. The couple run their own website clothing company.

Zeenat, 38, was diagnosed with breast cancer when she was just 32, that had already spread into her lungs and neck too.

14

She said: Id felt something wasnt right in my breast for a few months. It felt very tight.

"But I was focused on my career, working hard and there wasnt any time to think about anything else.

I should have got checked out and gone to the doctors earlier. I should have taken more notice because I found a lump in my neck about six months later - it had already spread.

A doctor took a biopsy and two days later I got a letter from the hospital telling me I had breast cancer.

14

It was such a shock. Id never checked my breasts either as I was so young, I never even gave breast cancer a second thought. I didnt think I needed to.

More than anything I wish that Id listened to my body earlier - and Id tell any other young woman to check themselves regularly and not ignore any changes.

Breast cancer can happen at a young age - as Sarah Harding knows. But early detection is vital.

"Because of the treatment I had, I havent been able to have children either, which has been heartbreaking for me.

14

ALL ABOARDSavvy mums swear by back-to-school stations to speed up busy mornings

FAST WORKWoman dazzles brother with surprise 24-hour kitchen makeover using bargain buys

CHEAP THRILLSShoppers share mega IKEA bargains such as 255 sofa for 30 & a cot under 20

STEPPING UPMum transforms grubby stairs for 10 using Poundland buys and her DIY skills

TOP SHELFDIY fan who couldnt afford shelving transforms old Ikea unit for almost nothing

CABINET SHUFFLEMum gives kitchen a makeover for 65 using B&Q tiles & sticky back plastic

Doctors discovered another lump in my right breast in 2017, and Ive had chemotherapy treatment for it. I have treatment every three weeks, and its keeping the cancer from spreading, which is good.

"Sarah will need a lot of support - the cancer support group Macmillan helped me so much.

"Sarah needs to know that although her cancer has spread, she will get through it. I am still here to prove that.

What is breast cancer and how does it spread?

Breast cancer is the most common type of cancer in the UK - with one woman diagnosed every ten minutes.

While most women can get breast cancer, it is most common in women who are over the age of 50.

According to Cancer Research UK, breast cancer starts in the breast tissue.

Breast cancer develops when abnormal cells in the breast begin to grow and divide in an uncontrolled way and eventually form a growth.

Most invasive breast cancers are found in the upper-outer quadrant of the breast.

If its not diagnosed and treated it can move through the lymph or blood vessels to other areas of the body.

Each year in the UK there are around 55,200 new breast cancer cases.

This equates to around 150 new cases a day.

It also accounts for 15 per cent of all new cancer cases each year.

If the cancer is diagnosed at its earliest stage then 98 per cent of people will survive the disease for five years or more.

If it is diagnosed at the latest stage, then just 26 per cent of people survive for five years or more.

What are the four stages of breast cancer?

Stage one:The cancer is small and only in the breast tissue - but can also be found in lymph nodes close to the breast.

Stage two:The cancer is either in the breast or in the nearby lymph nodes or both.

See the original post:
We were diagnosed with advanced breast cancer like Sarah Harding but we carried on living - The Sun

Recommendation and review posted by Bethany Smith

Eon Market Research Publish New Market Report On- CRISPR and Cas Genes Market 2020 Global Analysis, Size, Share, Trends and Growth, Forecast 2025

The CRISPR and Cas Genes Market Report also provides extensive research on the Top key players in this market and detailed insights into theircompetitiveness. Key business strategies such as acquisitions and acquisitions, alliances, collaborations, and contracts adopted by Top keyplayers are also recognized and analyzed in the report. For each Industry, the report recognizes competitors, product types, applications andspecifications, prices, Trends, and gross margins. The study analyzes the market in terms of revenue across all the major markets.

Market Summary :

Different Top key players such as CRISPR Therapeutics, AstraZeneca, Addgene, Caribou Biosciences, Inc., Cellectis, Editas Medicine, Inc., Egenesis, F. Hoffmann-La Roche Ltd., Horizon Discovery Group Plc, Genscrip, Danaher Corporation, Intellia Therapeutics, Inc., Lonza, Merck KGaA, New England BioLabs, Takara Bio, Inc. And More have been profiled to get better insights into the businesses. It offersdetailed elaboration on different Leading level industries which are functioning in global regions. Additionally, it gives detailedelaboration on different government rules, policies, and plans to understand the overall scope of the CRISPR and Cas Genes Market. In the global CRISPR and Cas Genes Market, various important aspects such as regional market insights, region-wise trends, country-level analysis,competitive landscape, company market share analysis, and key company profiles are covered. The latest CRISPR and Cas Genes Market report fine-tunes thescope of typical characteristics with which vendors are reviewed. For reviewing the global CRISPR and Cas Genes Market, the report uses varioustechniques such as surveys, interviews, and structured discussions with participants, end-users, and market leaders.

For Better Understanding Go With This Free Sample Report Enabled With Respective Tables and Figures( Get Instant 10% Discount ):https://www.eonmarketresearch.com/sample/72556

CRISPR and Cas Genes Market regional analysis covers the following regions North America, Europe, Asia-Pacific, South America, Middle East & Africa.

Product Segment Analysis of the Global CRISPR and Cas Genes Market are:

General Type

Applications of the Global CRISPR and Cas Genes Market are:

Biomedical

Buy This Premium Report: https://www.eonmarketresearch.com/buy/72556

Research Objectives Of CRISPR and Cas Genes Market:

* This report provides pin-point analysis for changing competitive dynamics

* It provides a forward-looking perspective on different factors driving or restraining the market growth

* It provides a six-year forecast assessed on the basis of how the market is predicted to grow

* It helps in understanding the key product segments and their future

* It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

* It helps in making informed business decisions by having complete insights of market and by making an in-depth analysis of market segments

Any Questions? Feel Free To Enquire Here. We will Put You On The Right Path: https://www.eonmarketresearch.com/enquiry/72556

Points To Buy This Market Report Covers:

* It will guide you in considering different perspectives on the market with the assistance of Porters five powers examination.

* Distinguish the new advancements, mark

* A valuation that each of these regions accounts for in the industry

Buyers who are searching for top-line data regarding CRISPR and Cas Genes market can get benefit from this report as its an essential resource which covers market size data, textual and graphical analysis of market growth trends and other economic information. In the resulting part, the report describes industry sales channels, distributors, traders, dealers, appendix and data sources.

[ *** If You Have Any Special Requirements, Please Let Us Know And We Will Offer You The Report As You Want. *** ]

About Us:

Eon Market Research (EMR) is a specialized market research, analytics, and solutions company, offering strategic and tactical support to clients for making well-informed business decisions. We are a team of dedicated and impassioned individuals, who believe strongly in giving our very best to what we do and we never back down from any challenge. Eon Market Research offers services such as data mining, information management, and revenue enhancement solutions and suggestions. We cater to industries, individuals, and organizations across the globe, and deliver our offerings in the shortest possible turnaround time.

Get in Touch with Us :

Eon Market Research

Phone: +1 703 879 7090

Email: [emailprotected]

Follow this link:
Global CRISPR and Cas Genes Market Insights And Extensive Research (2020-2025) : CRISPR Therapeutics, AstraZeneca, Addgene - The Daily Chronicle

Recommendation and review posted by Bethany Smith

One of the keys to bringing a viral outbreak under control is rapid detection and diagnosis, which depend on the availability of fast, low-cost, easy-to-use tests that dont require labs or expensive equipment to process them. Scientists at the Broad Institute of MIT and Harvard and collaborators in the United States, Nigeria, and Sierra Leone have now validated such tests for Ebola and Lassa two of the deadliest and most transmissible human viruses in settings with limited infrastructure. The work appears inNature Communications.

The diagnostic tests use theCRISPR-based SHERLOCK assayto detect low levels of virus in patient samples and generate either a fluorescent readout or a result on a paper strip. The test can be tailored to detect specific viruses from certain regions, requires only a simple heat block and basic supplies to run, costs less than US$1 per sample, could be used on saliva or urine eliminating the need for blood draws and can return results in less than an hour.

The tests also use a rapid chemical and heat treatment calledHUDSONto inactive the virus in patient samples. HUDSON makes the patient samples safer for clinical staff to handle in a low-tech environment, and eliminates the need to extract a viruss genetic material from the samples before analyzing.

Read more at the Broad Institute of MIT

Read the original:
CRISPR-based tests detects Lassa and Ebola in real-time - Outbreak News Today

Recommendation and review posted by Bethany Smith

Fort Collins, Colorado Reports Globe recently published a report on the CRISPR Market. The study was supported by data obtained either from primary sources or from corporate databases. The experts in the market have confirmed that the data is realistic and relevant to the particular market conditions and therefore will prove extremely helpful to the user. The factors that have been broken down into driver and restraint systems. The regions, types, applications, and strategies are segmented and subdivided for better and better understanding.

This report covers the current economic impact of COVID-19. This outbreak drastically changed the global economic situation. The current scenario of the constantly evolving corporate sector, as well as the present and future assessment of the impact, are also addressed in the report.

Global CRISPR Market Size Study by Application(Genome Editing, Genetic Engineering, Gene Library, CRISPR Plasmid, Human Stem cells, Genetically Modified Organism, Cell Line Engineering), by End-User (Biotechnology Companies, Pharmaceutical Companies, Academic Institutes, Research & Development Institutes) and Regional Forecast 2017-2025.

The CRISPR marketreport gives a 360 approach for a holistic understanding of the market scenario. It relies on authentically-sourced information and an industry-wide analysis to predict the future growth of the sector. The study gives a comprehensive assessment of the CRISPR industry, along with market segmentation, product types, applications, and value chain.

Leading CRISPR manufacturers/companies operating at both regional and global levels:

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

Research Objective:

Our panel of trade analysts has taken immense efforts in doing this group action in order to produce relevant and reliable primary & secondary data regarding the CRISPR market. Also, the report delivers inputs from the trade consultants that will help the key players in saving their time from the internal analysis. Readers of this report are going to be profited with the inferences delivered in the report. The report gives an in-depth and extensive analysis of the CRISPR market.

The CRISPR Market is Segmented:

By Applications:

By End User:

This CRISPR report umbrellas vital elements such as market trends, share, size, and aspects that facilitate the growth of the companies operating in the market to help readers implement profitable strategies to boost the growth of their business. This report also analyses the expansion, market size, key segments, market share, application, key drivers, and restraints.

CRISPR Market Regional Analysis:

Key Coverage of Report:

Key insights of the report:

How Reports Globe is different than other Market Research Providers

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Contact us:

Mr. Mark Willams

Account Manager

US: +1-970-672-0390

Email:[emailprotected]

Web:reportsglobe.com

Read the original here:
CRISPR Market Size and Growth 2020-2027 | Major Players Thermo Fisher Scientific, Editas Medicine, Caribou Biosciences, CRISPR Therapeutics AG,...

Recommendation and review posted by Bethany Smith

The following report offers a comprehensive and an in detail assessment of the CRISPR Genome Editing market and focuses on the key growth contributors of the market to help the clients better understand the current scenario of the market while taking into account the history of the market over the past years as well as the future scope of growth and forecast that have also been discussed in depth in the following report. The report covers most of the global regions such as APAC, North America, South America, Europe, Middle East and Africa, hence ensuring a global and evenly distributed growth curve as the market matures over the time.

Top Market Players covered in this report are: Editas Medicine, CRISPR Therapeutics, Horizon Discovery, Sigma-Aldrich, Genscript

The report takes into account the important factors and aspects that are crucial to the client to post good growth and establish themselves in the CRISPR Genome Editing market. Some of these aspects are sales, revenue, market size, mergers and acquisitions, risks, demands, new trends and technologies and much more are taken into consideration to give a complete and detailed understanding of the market conditions.

Get Sample PDF [emailprotected]https://www.reportsintellect.com/sample-request/1341725?ata

Description:

This report has the updated data on the CRISPR Genome Editing market and as the international markets have been changing very rapidly over the past few years the markets have gotten tougher to get a grasp of and hence the analysts here at Reports Intellect have prepared a detailed report while taking in consideration the history of the market and a very detailed forecast along with the market issues and their solution.

The given report focuses on the key aspects of the markets to ensure maximum benefit and growth potential for clients and our extensive analysis of the market will help the clients to achieve this much more efficiently. The report has been prepared by using primary as well as secondary analysis in accordance with porters five force analysis which has been a game-changer for many in the CRISPR Genome Editing market. The research sources and tools used to assess the report are highly reliable and trustworthy.

CRISPR Genome Editing Market Type Coverage:

Genetic EngineeringGene LibraryHuman Stem Cells

CRISPR Genome Editing Market Application Coverage:

Biotechnology CompaniesPharmaceutical Companies

Market Segment by Regions and Nations included:

North America (United States,

Canada, Mexico)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia)

South America (Brazil, Argentina, Colombia, etc.)

Europe, Middle East and Africa (Germany, France, UK, Russia and Italy, Saudi Arabia, UAE, Egypt, Nigeria, South Africa)

Discount PDF Brochure @https://www.reportsintellect.com/discount-request/1341725?ata

Competitive Analysis:

The report offers effective guidelines and recommendations for players to secure a position of strength in the CRISPR Genome Editing market. The newly arrived players in the market can up their growth potential by a great amount and also the current dominators of the market can keep up their dominance for a longer time by the use of this report.

The report includes the detailed description of mergers and acquisitions will help you to get a complete idea of the market competition and also give you extensive knowledge on how to excel ahead and grow in the market.

Reasons to buy:

About Us:

Reports Intellect is your one-stop solution for everything related to market research and market intelligence. We understand the importance of market intelligence and its need in todays competitive world.

Our professional team works hard to fetch the most authentic research reports backed with impeccable data figures which guarantee outstanding results every time for you.So whether it is the latest report from the researchers or a custom requirement, our team is here to help you in the best possible way.

Contact Us:

[emailprotected]Phone No: + 1-706-996-2486US Address:225 Peachtree Street NE,Suite 400,`Atlanta, GA 30303

Read the rest here:
CRISPR Genome Editing Market 2020 to 2025 Trends & Regional Revenue By: Editas Medicine, CRISPR Therapeutics, Horizon Discovery, Sigma-Aldrich,...

Recommendation and review posted by Bethany Smith

This market research report includes a detailed segmentation of the global genome editing market by technology (CRISPR, TALEN, ZFN, and Others), by application (Cell Line Engineering, Genetic Engineering, and Others), By end-user (Research Institutes, Biotechnology and Pharmaceutical Companies, and Contract Research Organizations), by regions (North America, Europe, Asia Pacific, and Rest of the World).

Overview of the Global Genome Editing Market

Infoholics market research report predicts that the Global Genome Editing Market will grow at a CAGR of 14.4% during the forecast period. The market has witnessed steady growth in the past few years with the development in technology and the introduction of highly sensitive, robust, and reliable systems in the market. The market is fueled due to increase in genetic disorders, increasing investment and funds, and technological advancements in genome editing.

Request For Report sample @ https://www.trendsmarketresearch.com/report/sample/9845

The market continues to grow and is one of the increasingly accepted market in many countries worldwide. Vendors are focusing towards obtaining funds and collaborating with universities to enlarge their research and development capabilities. The majority of the revenue is generated from the leading players in the market with dominating sales of ThermoFisher Scientific, GenScript Corp., Sangamo Therapeutics, Lonza Group, and Horizon Discovery Group plc.

According to Infoholic Research analysis, North America accounted for the largest share of the global genome editing market in 2018. US dominates the market with majority of genome editing companies being located in this region. However, China has not been too far behind and has great government support for the research in genome editing field.

Request For Report Discounts @ https://www.trendsmarketresearch.com/report/discount/9845

Genome Editing Market by Technology:

In 2018, the CRISPR segment occupied the largest share due to specific, effective, and cost-effective nature of the technology. Many companies are focusing on providing genome editing services. For instance, in January 2019, Horizon Discovery extended CRISPR screening service to primary human T cells.

Genome Editing Market by Applications:

In 2018, the cell line engineering accounted the maximum share followed by genetic engineering. Increase in the number of people suffering with genetic disorders has driven the growth of the genome editing market.

Genome Editing Market by End Users:

In 2018, the biotechnology and pharmaceutical companies gained the highest market share for genome editing market due to increased pervasiveness of cancer and infectious diseases are driving research goings-on in biotechnology & pharmaceutical companies segment.

Genome Editing Market by Regions:

The market is dominated by North America, followed by Asia Pacific and Europe. The major share of the North America market is from the US due to quick adoption of new and advanced technologies.

Genome Editing Market Research Competitive Analysis The market is extremely fragmented with several smaller companies struggling for market share. Big pharmaceutical establishments have also united with venture capitalists to provide funding to the start-ups. In 2015, Bayer financed $335 million and in the very same year, Celgene combined with Abingworth invested $64 million in CRISPR Therapeutics. The NIH recently granted 21 somatic cell genome editing grants of almost $86 million over the next half a decade. These endowments are the foremost to be granted through the Somatic Cell Genome Editing (SCGE) program that was initiated in January 2018 with NIH Common Fund.

The companies are collaborating and licensing to increase their capabilities in the market. CRISPR, TALEN, ZFN, Meganuclease, ARCUS, and RTDS are some of the key technology areas concentrated by key players in the market. Since 2015, the deals on the CRISPR technology has drastically increased.

Key vendors:

Key competitive facts

Benefits The report provides complete details about the usage and adoption rate of genome editing market. Thus, the key stakeholders can know about the major trends, drivers, investments, vertical players initiatives, and government initiatives towards the healthcare segment in the upcoming years along with details of the pureplay companies entering the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders in order to expand their business and capture the revenue in specific verticals, and to analyze before investing or expanding the business in this market.

Key Takeaways:

More Info of Impact Covid19 @ https://www.trendsmarketresearch.com/report/covid-19-analysis/9845

Excerpt from:
Genome Editing Market Insights on Upcoming Trends the COVID-19 - Kentucky Journal 24

Recommendation and review posted by Bethany Smith

Global Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology Market: Overview Comprehensive, well-verified and minutely analyzed research postulates articulated in the report allow stakeholders such as market participants, suppliers, industry behemoths, supply chain professionals amongst others to derive insightful references from this well-composed research report, such that significant stakeholders can well derive relevant information based on which impeccable revenue oriented business discretion may be directed to ensure long-term stability and sustenance in the Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology market .

Further, relevant inputs on M&A developments, business partnership, collaborations and commercial agreements have also been touched upon in this report on Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology market.

The study encompasses profiles of major companies operating in the Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology Market. Key players profiled in the report includes:Thermo Fisher ScientificMerckGenScriptIntegrated DNA TechnologiesHorizon Discovery GroupAgilent TechnologiesCellectaGeneCopoeiaNew England BiolabsOrigene TechnologiesSynthego CorporationToolgen

In tandem with aforementioned factors presented in the report of the target market, this crucial report channelized is directed to render complete review and analysis about a range of market based information comprising market revenue contributing processes, as well as numerous other high end information and data synthesis with respect to the aforementioned Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology market.

Investing in the Report: Know Why A thorough evaluation to investigate material sources and downstream purchase developments are echoed in the reportThis report aims to holistically characterize and classify the Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology market for superlative reader understandingElaborate references on purchaser needs, barrier analysis and opportunity assessment are also ingrainedThe report surveys and makes optimum forecast pertaining to market volume and value estimation

Access Complete Report @ https://www.orbismarketreports.com/global-clustered-regularly-interspaced-short-palindromic-repeatscrispr-technology-market-size-status-and-forecast-2019-2025?utm_source=Puja

Global Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology Market: Understanding SegmentationBesides presenting notable insights on Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology market factors comprising above determinants, the report further in its subsequent sections of this detailed research report on Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology market states information on regional segmentation, as well as thoughtful perspectives on specific understanding comprising region specific developments as well as leading market players objectives to trigger maximum revenue generation and profits in the near future according to elaborate speculations.

By the product type, the market is primarily split into ProductsServices

By the end-users/application, this report covers the following segments Biomedical ApplicationsAgricultural ApplicationsIndustrial ApplicationsBiological Research

The key regions covered in the Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology market report are:North America (U.S., Canada, Mexico)South America (Cuba, Brazil, Argentina, and many others.)Europe (Germany, U.K., France, Italy, Russia, Spain, etc.)Asia (China, India, Russia, and many other Asian nations.)Pacific region (Indonesia, Japan, and many other Pacific nations.)Middle East & Africa (Saudi Arabia, South Africa, and many others.)

Scope of the ReportThe discussed Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology market has been valued at xx million US dollars in 2019 and is further projected to grow at xx million US dollars through the forecast span till 2024, growing at a CAGR of xx% through the forecast period.

Place Inquiry for Buying or Customization of [emailprotected] https://www.orbismarketreports.com/enquiry-before-buying/64954?utm_source=Puja

Some Strategic Factors Coated in Desk of Content of Global Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology Market:Chapter 1: Introduction, market driving drive product Objective of Study and Analysis Scope.Chapter 2: Exclusive Summary the fundamental info of the Global Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology Market.Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges of the Global Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology Market.Chapter 4: Presenting the Global Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology Market Factor Evaluation Porters Five Forces, Supply/Value Chain, PESTEL evaluation, Market Entropy, Patent/Trademark Analysis.

What To Expect From The ReportA complete analysis of the Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology marketConcrete and tangible alterations in market dynamicsA thorough study of dynamic segmentation of the Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology marketA complete review of historical, current as well as potential foreseeable growth projections concerning volume and valueA holistic review of the vital market alterations and developmentsNotable growth friendly activities of leading players

(*If you have any special requirements, please let us know and we will offer you the report as you want.)

About Us : With unfailing market gauging skills, has been excelling in curating tailored business intelligence data across industry verticals. Constantly thriving to expand our skill development, our strength lies in dedicated intellectuals with dynamic problem solving intent, ever willing to mold boundaries to scale heights in market interpretation.

Contact Us : Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: USA: +1 (972)-362-8199 | IND: +91 895 659 5155

Original post:
Global Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology Market 2025 Maximum Benefit and Growth Potential During this COVID...

Recommendation and review posted by Bethany Smith

Report is a detailed study of the Gene Editing Service market, which covers all the essential information required by a new market entrant as well as the existing players to gain a deeper understanding of the market.The primary objective of this research report named Gene Editing Service market is to help making reliable strategic decisions regarding the opportunities in Gene Editing Service market. It offers business accounts, industry investors, and industry segments with consequential insights enhancing decision making ability.[emailprotected] or call us on +1-312-376-8303.

Request Report from CMR Website:https://cognitivemarketresearch.com/pharma-%26-healthcare/gene-editing-service-market-report

Global and Regional Gene Editing Service Market Segmentation by Type: Ex-Vivo, In-Vivo

Global Gene Editing Service Market Segmentation by Applications: Commercial, Academic Research

Major Market Players with an in-depth analysis: Caribou Biosciences, CRISPR Therapeutics, Merck KGaA, Editas Medicine, Thermo Fisher Scientific, Horizon Discovery, Genscript Biotech, GeneCopoeia, Integrated DNA Technologies, Eurofins Genomics, DNA 2.0 (ATUM), BBI Life Sciences, Genewiz, Gene Oracle, SBS Genetech, Bio Basic

Request Free Sample Copy of Gene Editing Service Market Research [emailprotected] https://cognitivemarketresearch.com/pharma-%26-healthcare/gene-editing-service-market-report#download_report

The Gene Editing Service market report offers the current state of the market around the world. The report starts with the market outline and key components of the Gene Editing Service market which assumes a significant job for clients to settle on the business choice. It additionally offers the key focuses to upgrade the development in the Gene Editing Service market. Some fundamental ideas are likewise secured by reports, for example, item definition, its application, industry esteem chain structure and division which help the client to break down the market without any problem. Also, the report covers different factors, for example, arrangements, efficient and innovative which are affecting the Gene Editing Service business and market elements.

Any query? Enquire Here For Discount (COVID-19 Impact Analysis Updated Sample): Click Here>Download Sample Report of Gene Editing Service Market Report 2020 (Coronavirus Impact Analysis on Gene Editing Service Market)

The research comprises primary information about the products. Similarly, it includes supply-demand statistics, and segments that constrain the growth of an industry. It also includes raw materials used and manufacturing process of Gene Editing Service market. Additionally, report provides market drivers and challenges & opportunities for overall market in the particular provincial sections.

Competitive Analysis has been done to understand overall market which will be helpful to take decisions. Major players involved in the manufacture of Gene Editing Service product has been completely profiled along with their SWOT. Some of the key players include Caribou Biosciences, CRISPR Therapeutics, Merck KGaA, Editas Medicine, Thermo Fisher Scientific, Horizon Discovery, Genscript Biotech, GeneCopoeia, Integrated DNA Technologies, Eurofins Genomics, DNA 2.0 (ATUM), BBI Life Sciences, Genewiz, Gene Oracle, SBS Genetech, Bio Basic. It helps in understanding their strategy and activities. Business strategy described for every company helps to get idea about the current trends of company. The industry intelligence study of the Gene Editing Service market covers the estimation size of the market each in phrases of value (Mn/Bn USD) and volume (tons). Report involves detailed chapter on COVID 19 and its impact on this market. Additionally, it involves changing consumer behavior due to outbreak of COVID 19.

Further, report consists of Porters Five Forces and BCG matrix as well as product life cycle to help you in taking wise decisions. Additionally, this report covers the inside and out factual examination and the market elements and requests which give an entire situation of the business.

Regional Analysis for Gene Editing Service North America (United States, Canada)Europe (Germany, Spain, France, UK, Russia, and Italy)Asia-Pacific (China, Japan, India, Australia, and South Korea)Latin America (Brazil, Mexico, etc.)The Middle East and Africa (GCC and South Africa)

DOWNLOAD FREE SAMPLE [emailprotected]: https://cognitivemarketresearch.com/pharma-%26-healthcare/gene-editing-service-market-report#download_report

Chapters Define in TOC (Table of Content) of the Report:Chapter 1: Market Overview, Drivers, Restraints and Opportunities, SegmentationOverviewChapter 2: COVID ImpactChapter 3: Market Competition by ManufacturersChapter 4: Production by RegionsChapter 5: Consumption by RegionsChapter 6: Production, By Types, Revenue and Market share by TypesChapter 7: Consumption, By Applications, Market share (%) and Growth Rate byApplicationsChapter 8: Complete profiling and analysis of ManufacturersChapter 9: Manufacturing cost analysis, Raw materials analysis, Region-wiseManufacturing expensesChapter 10: Industrial Chain, Sourcing Strategy and Downstream BuyersChapter 11: Marketing Strategy Analysis, Distributors/TradersChapter 12: Market Effect Factors AnalysisChapter 13: Market ForecastChapter 14: Gene Editing Service Research Findings and Conclusion, Appendix, methodology and data source To check the complete Table of Content click here: @ https://cognitivemarketresearch.com/pharma-%26-healthcare/gene-editing-service-market-report#table_of_contents

The qualitative contents for geographical analysis will cover market trends in each region and country which includes highlights of the key players operating in the respective region/country, PEST analysis of each region which includes political, economic, social and technological factors influencing the growth of the market. The research report includes specific segments by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2027.

About Us: Cognitive Market Research is one of the finest and most efficient Market Research and Consulting firm. The company strives to provide research studies which include syndicate research, customized research, round the clock assistance service, monthly subscription services, and consulting services to our clients.

Contact Us: +1-312-376-8303Email: [emailprotected]Web: https://www.cognitivemarketresearch.com/

**********Download the Entire Report*************************************************https://cognitivemarketresearch.com/pharma-%26-healthcare/gene-editing-service-market-report

Read the original:
Coronavirus Impact Editon of Gene Editing Service Coronavirus Impact Editon of Future Development, Top Manufacturers, Technological Advancement,...

Recommendation and review posted by Bethany Smith

Germline genetic testing is a key component of prostate cancer treatment, and broader testing criteria combined with reduced barriers to these tests could result in better informed care, including preventive surveillance, according to data from a recent study.1

Results from the retrospective study done in a total of 986 patients with prostate cancer who participated in a sponsored testing program showed that 16% (n = 153) of patients who underwent genetic testing had positive germline result; of these patients, 14% (n = 138) had pathogenic (P)/likely pathogenic (LP) variants and 1.5% (n = 15) had increased risk alleles (IRAs). Moreover, these patients were found to have 167 P/LP variants in 31 genes, as well as 19 IRAs in APC and HOXB13.

A total of 129 patients with P/LP variants had staging data available. This information indicated that 70 patients had very high-risk disease (stage III/IV), 23 had high-risk disease (stage III), and 36 had intermediate- to low-risk disease (stage IIa, IIb, and IIc). Among patients who had P/LP variants or risk alleles, only 36% reported having a family history of prostate, breast, ovarian, or pancreatic cancer.

Our initial findings from this study of [patients with] prostate cancer found an overall positive rate of 16% with 75% of positive patients being eligible for implementation of gene-specific management guidelines, precision therapies and/or clinical treatment trials, the study authors wrote. Of patients with P/LP variants, 64% did not have a close family history of prostate, breast, ovarian, or pancreatic cancer, and therefore would not have been eligible for testing based on National Comprehensive Cancer Network (NCCN) criteria.

Current criteria for germline testing in patients who have been diagnosed with prostate cancer may present a barrier to some individuals, especially those who dont have specific features regarding personal or family history, according to the investigators. Previous data have suggested that these testing criteria can exclude patients who actually harbor germline variants, which could potentially lead to suboptimal care.2

To address this, investigators launched a sponsored testing program aimed at increasing access to germline genetic testing for patients with prostate cancer through the utilization of broader criteria and eliminating cost barriers.

The program launched in July 2019 and continued throughout October 2019. Each patient enrolled on the program underwent testing that included an 84-gene, multicancer germline panel. Positive results included P and LP variants as well as IRAs. Of the 986 patients enrolled, the majority, or 70% (n = 692), were Caucasian, 13% were African American (n = 127), 3% were Hispanic (n = 33), 1.7% were Ashkenazi Jewish (n = 17), 1.0% were Asian (n = 10), and the remaining 11% (n = 107) were of unreported, mixed, or other ethnicity.

Additional results showed that when investigators evaluated diagnostic yield by disease stage, the very high-risk subgroup had a positive rate of 16%, the high-risk subgroup had a positive rate of 17%, and the intermediate- to low-risk subgroup had a positive rate of 14%.

Overall, no association of statistical significance was observed between disease stage and germline positive rate. The intermediate-/low-risk patients, who would not be indicated for germline testing based on current guidelines, had a positive rate of 14% (including P/LP variants and IRAs), the study authors wrote. Of the 36 intermediate-/low-risk patients with positive variants, 27(75%) had variants in clinically actionable genes.

Notably, 71% of patients who tested positive had P/LP variants that confers eligibility for gene-specific targeted agents or clinical trials based on variants in homologous repair or mismatch repair genes, the authors added.

These data imply that broader testing criteria could help to better inform care for many patients who might otherwise be overlooked for testing, according to the authors. By reducing barriers to testing, the authors conclude that more patients with prostate cancer would have access to crucial actionable genetic information that could lead to more targeted treatment approaches that could potentially improve outcomes.

New Recommendations Call for Increased Access to Germline Testing

The 2019 Philadelphia Prostate Cancer Consensus Conference, which brought together healthcare experts, stakeholders, and leaders from national organizations, was held to address challenges with germline testing in clinical practice and to map out a framework to increase accessibility to testing in the precision medicine era.

To do this, the panel set 3 goals: to define optimal germline testing approaches that comprise expanded panel testing options and evolving genetic data, to determine consistent germline testing indications and management, and to establish alternative genetic evaluation models in order to compensate for the shortage of genetic counseling services.3

A total of 97 participants attended the conference; these included experts in urology, medical oncology, radiation oncology, clinical genetics, and genetic counseling spaces, among others. In total, 76 participants were included on the final voting panel.

Panel members conducted a literature review with thematic topics that focused on prostate cancer risk, germline mutations by clinical and molecular characteristics of the disease, clinical multigene testing data, germline mutations in diverse populations, genetic testing capabilities and considerations, genetic counseling implementation, NCCN genetic testing guidelines, genetic testing for precision medicine in the metastatic setting, germline implications for active surveillance of early-stage disease, and germline implications for early disease detection.

Large germline panels and somatic testing were recommended for metastatic prostate cancer. Reflex testing to examine priority genes followed by expanded testing was recommended for several scenarios. Investigators determined these priority genes to be BRCA1/2 and mismatch repair genes with regard to metastatic disease treatment, and ATM in broader testing to help determine clinical trial eligibility. Additionally, BRCA2 was suggested for active surveillance discussions.

Upon completion of their review, the panel established criteria for germline prostate cancer genetic testing. Men with metastatic disease, including those with castration-resistant or castration-sensitive prostate cancer, meet the criteria for testing. In order for patients with nonmetastatic disease to be considered for genetic testing, they must either be of Ashkenazi Jewish ancestry, have advanced disease, have intraductal or ductal pathology, or be grade group 4 (Gleason sum 8) or above. Patients who have a brother or father, or 2 or more male relatives, who received a prostate cancer diagnosis and were under 60 years of age, who died from prostate cancer, or who had metastatic disease should also be considered for testing.

For those with metastatic disease, priority germline testing was recommended for those with BRCA1/2, DNA MMR genes, and further gene testing based on family history. Somatic next-generation sequencing was recommended for all men with metastatic disease. Additionally, confirmatory germline testing for somatic mutations was recommended for those with BRCA2 genes.

Reflex testing may be optimal for patients with nonmetastatic disease, according to the panel. with a recommendation to test for BRCA2 variants. For patients without a prostate cancer diagnosis but with an applicable family history, priority genes for risk assessment include BRCA2 and HOXB13.

References:

Read more:
Increased Access to Germline Testing Needed in Prostate Cancer - OncLive

Recommendation and review posted by Bethany Smith

Amy Edgar, APRN, CRNP, FNP-C, is an inspiring nurse practitioner seeking to change healthcare from the inside and embrace the superpowers of our next generation of humans. Weaving the threads of mom, entrepreneur, teacher, nurse, primary care provider, and science geek, she founded the Children's Integrated Center for Success in 2014. Ignited by her experience raising her now 16-year old daughter, Amy unites systems thinking and integrated care delivery models to create a primary care center focused on children with behavioral health needs. From the latest in genetics research, to nutrition, to occupational therapy and speech, to art and equine therapy, to staffing school advocates and marriage counselors -- CICS strives to have the answers their families need to reach every child, every time. In 2017, Amy led CICS to better connect career opportunities for children with autism looking for suitable work to capture their own piece of the American Dream, which has pioneered the CICS Foundation and Maker Lab.

See more here:
How Genetic Testing Will Transform Mental Health Care - Fox 4

Recommendation and review posted by Bethany Smith

This article is thefirst of a three-part conversation onBRCA1 and BRCA2 gene mutations.

Mutations in the BRCA1 and BRCA2 genes are linked to the development of breast cancer, ovarian cancer and other types of cancer.

Genetic testing and counseling services can determine whether a person carries these mutations and, if they do, how the information could help inform cancer prevention or treatment decisions.

In the first of a three-part conversation, Kara Milliron, a genetic counselor at the University of Michigan Rogel Cancer Center's Breast and Ovarian Cancer Risk Evaluation Clinic, discusses some of the ins and outs of BRCA gene mutations.

Both the BRCA1 and BRCA2 genes, which we all carry, play a role in making sure cells grow at the proper rate.

They act like a brake on a car, Milliron explains. When there is a change or a mutation in BRCA1 or BRCA2, those genes don't work properly, and that's where we see an increased risk for developing cancer.

These mutations can be passed down in families. Inherited susceptibility, which includes BRCA1 and BRCA2, are responsible for about 5% to 10% of breast cancers and 20% of ovarian cancers.

Thats why its important to know your family history, she says. We encourage people to try to go back three generations back to your grandparents.

Genetic counselors are on the lookout for clues in family histories that may indicate an increased risk of carrying a mutation in a cancer susceptibility gene, such as cancers that occur before the age of 50, or the occurrence of more rare cancers, such as ovarian cancer, fallopian tube cancer, primarily peritoneal carcinomatosis, pancreas cancer and male breast cancer.

When we see breast and ovarian cancer in the same individual, or when we see a rare type of melanoma called ocular melanoma, that makes us a little bit concerned about an inherited susceptibility, Milliron says. So, there are some clues that we see in the family history that make us a little bit more suspicious that there may be a gene change that's being passed on in the family.

While BRCA1 and BRCA2 mutations are most frequently talked about in relation to breast and ovarian cancers, its important to know that theyve been linked to other types of cancer as well, Milliron stresses.

Men in particular are somewhat forgotten with regards to these two genes because the cancer risks or the cancer burden is lower in men but it does have significant consequences, if a man does carry a BRCA1 or BRCA2 gene mutation, she says. They have a higher risk for developing prostate cancer and those prostate cancers tend to be more aggressive.

Genetic testing is recommended where theres a family history of aggressive prostate cancers with a Gleason score of seven or higher. And for men diagnosed with one of these aggressive prostate cancers or with metastatic prostate cancer.

Continue reading here:
BRCA1 and BRCA2 Gene Mutations: The Basics - University of Michigan Health System News

Recommendation and review posted by Bethany Smith

The globalNewborn and Prenatal Genetic Testing Marketis carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Newborn and Prenatal Genetic Testing market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the global Newborn and Prenatal Genetic Testing market. With qualitative and quantitative analysis, we help you with thorough and comprehensive research on the global Newborn and Prenatal Genetic Testing market. We have also focused on SWOT, PESTLE, and Porters Five Forces analyses of the global Newborn and Prenatal Genetic Testing market.

Leading players of the global Newborn and Prenatal Genetic Testing market are analyzed taking into account their market share, recent developments, new product launches, partnerships, mergers or acquisitions, and markets served. We also provide an exhaustive analysis of their product portfolios to explore the products and applications they concentrate on when operating in the global Newborn and Prenatal Genetic Testing market. Furthermore, the report offers two separate market forecasts one for the production side and another for the consumption side of the global Newborn and Prenatal Genetic Testing market. It also provides useful recommendations for new as well as established players of the global Newborn and Prenatal Genetic Testing market.

To know How COVID-19 Pandemic Will Impact Newborn and Prenatal Genetic Testing Market/Industry -Request sample copy of this report:https://www.reporthive.com/request_sample/2435212

Major Players:

Perkin ElmerAriosa DiagnosticsAgilent Technologies, Inc.Verinata HealthIllumina, Inc.Sequenom, Inc.CapitalBio MedLabNatera, Inc.Bio-Rad Laboratories, Inc.BGI

Segmentation by Product:

PCRFISHaCGHNIPTMSS

Segmentation by Application:

HospitalClinicOthers

Regions and Countries:U.S, Canada, France, Germany, UK, Italy, Rest of Europe, India, China, Japan, Singapore, South Korea, Australia, Rest of APAC, Brazil, Mexico, Argentina, Rest of LATAM, Saudi Arabia, South Africa, UAE.

Report Objectives

For More Information or Query or Customization Before Buying, Visit at -:https://www.reporthive.com/request_customization/2435212

Table of Contents

Report Overview:It includes major players of the global Newborn and Prenatal Genetic Testing market covered in the research study, research scope, and Market segments by type, market segments by application, years considered for the research study, and objectives of the report.

Global Growth Trends:This section focuses on industry trends where market drivers and top market trends are shed light upon. It also provides growth rates of key producers operating in the global Newborn and Prenatal Genetic Testing market. Furthermore, it offers production and capacity analysis where marketing pricing trends, capacity, production, and production value of the global Newborn and Prenatal Genetic Testing market are discussed.

Market Share by Manufacturers:Here, the report provides details about revenue by manufacturers, production and capacity by manufacturers, price by manufacturers, expansion plans, mergers and acquisitions, and products, market entry dates, distribution, and market areas of key manufacturers.

Market Size by Type:This section concentrates on product type segments where production value market share, price, and production market share by product type are discussed.

Market Size by Application:Besides an overview of the global Newborn and Prenatal Genetic Testing market by application, it gives a study on the consumption in the global Newborn and Prenatal Genetic Testing market by application.

Production by Region:Here, the production value growth rate, production growth rate, import and export, and key players of each regional market are provided.

Consumption by Region:This section provides information on the consumption in each regional market studied in the report. The consumption is discussed on the basis of country, application, and product type.

Company Profiles:Almost all leading players of the global Newborn and Prenatal Genetic Testing market are profiled in this section. The analysts have provided information about their recent developments in the global Newborn and Prenatal Genetic Testing market, products, revenue, production, business, and company.

Market Forecast by Production:The production and production value forecasts included in this section are for the global Newborn and Prenatal Genetic Testing market as well as for key regional markets.

Market Forecast by Consumption:The consumption and consumption value forecasts included in this section are for the global Newborn and Prenatal Genetic Testing market as well as for key regional markets.

Value Chain and Sales Analysis:It deeply analyzes customers, distributors, sales channels, and value chain of the global Newborn and Prenatal Genetic Testing market.

Key Findings:This section gives a quick look at important findings of the research study.

About us:

Our research base consists of a wide spectrum of premium market research reports. Apart from comprehensive syndicated research reports, our in-house team of research analysts leverages excellent research capabilities to deliver highly customized tailor-made reports. The market entry strategies presented in our reports has helped organizations of all sizes to generate profits by making timely business decisions. The research information including market size, sales, revenue, and competitive analysis offered, is the product of our excellence in the market research domain.

Here is the original post:
Impact of Corona on Newborn and Prenatal Genetic Testing Market : What will prove favorable for Newborn and Prenatal Genetic Testing Market? - The...

Recommendation and review posted by Bethany Smith

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Direct-to-Consumer Genetic Testing market.

Trusted Business Insights presents an updated and Latest Study on Direct-to-Consumer Genetic Testing Market 2019-2029. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Direct-to-Consumer Genetic Testing market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Direct-to-Consumer Genetic Testing Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19)

Abstract, Snapshot, Market Analysis & Market Definition: Direct-to-Consumer Genetic Testing MarketIndustry / Sector Trends

Direct-to-Consumer Genetic Testing Market size was valued at USD 831.5 million in 2018 and is expected to witness 15.2% CAGR from 2019 to 2025.

U.S. DTC Genetic Testing Market Size, By Test Type, 2018 & 2025 (USD Million)

Rising prevalence of genetic diseases such as cystic fibrosis and Alzheimers globally is one of the major factors fostering direct-to-consumer genetic testing market growth. According to Global Genes, over 300 million people globally suffer from rare diseases. Recently developed DTC genetic tests allows consumer to identify probability of acquiring a specific genetic disease. Therefore, increasing adoption of DTC genetic testing for early disease detection and identification of genetic diseases will boost the industry growth over forecast timeline.

Increasing demand for personalized medications to treat genetic diseases will positively impact industry growth in forthcoming years. Individuals genome must be tested to develop personalized medicines. This increases the demand for DTC genetic kits since, it provides detailed information about individuals genetic predisposition. As detailed information regarding genetic makeup of individuals is easily available with the use of DTC genetic kits, researchers can easily design and develop personalized medicine that would help in faster patient recovery. Aforementioned factor is expected to drive the industry growth. However, high cost of DTC genetic testing kits may hamper industry growth to some extent during the forecast period.

Market Segmentation, Outlook & Regional Insights: Direct-to-Consumer Genetic Testing Market

Direct-to-Consumer Genetic Testing Market, By Test Type

Predictive testing segment will experience around 17% growth throughout the analysis period. Considerable segmental growth can be associated with rising prevalence of genetic diseases. Recently developed DTC genetic tests help to identify mutations that increase the chances of acquiring specific disease accurately. Surging awareness regarding benefits of such presymptomatic testing has reduced the mortality rates by enabling effective management of disease. Above mentioned factors have stimulated the segmental growth that is predicted to continue over the forecast timeframe.

Ancestry and relationship testing segment accounted for over 43% revenue share in 2018. Increasing awareness regarding ethnicity tests amongst the American and European population has increased the demand for DTC genetic tests. Accuracy and efficiency possessed by these tests has fostered segmental growth. Moreover, ancestry tests developed by companies such as Ancestry.com are user friendly. Availability of robust DTC ancestry tests providing meaningful clinical, genealogical and even forensic information will positively impact the segment growth.

Direct-to-Consumer Genetic Testing Market, By Technology

Targeted analysis segment was valued over USD 310 million in 2018. Targeted analysis is utilized for determining the defects in genes that are responsible for a particular disorder. Targeted genotyping can accurately measure an individuals gene pool that encodes important information regarding various diseases. Targeted analysis can be conducted at significant low cost compared to other available techniques that should augment its adoption rate over forecast timeframe.

Single nucleotide polymorphism segment will experience around 15% growth throughout the forecast period. Single nucleotide polymorphism chips specifically detect changes in single nucleotide that increases the efficiency of tests. For instance, SNP chips utilized for diagnosing hereditary cancers have detected 1300 mutations in BRCA2 genes. Various companies such as Ancestry.com and Color Genomics utilize SNP arrays that analyse gene sequences at a specific resolution and reveal detailed analysis about the defective genes that may in future cause certain disease. Increasing adoption of such advanced SNP chips in DTC testing kits will trigger the segmental growth.

Germany DTC Genetic Testing Market Size, By Technology, 2018 (USD Million)

Direct-to-Consumer Genetic Testing Market, By Region

North America direct-to-consumer genetic testing market accounted for around 39% regional share in 2018. Regional market growth can be attributed to increasing prevalence of genetic diseases. Rare genetic diseases such as thalassemia, hemophilia and anaemia require continuous and critical monitoring. According to CDC, every year more than 1,000 people are affected by thalassemia. Furthermore, American population has higher literacy rate and also, awareness regarding DTC tests is high amongst the American population that augments demand for DTC genetic tests.

Europe is estimated to experience around 15% growth over the coming years. European direct-to-consumer genetic testing market is highly regulated and for carrying out some of the genetic tests through DTC kits, customers are required to have physicians prescription. However, currently, European regulatory bodies are working on improving regulations set on DTC tests due to improved accuracy and efficiency possessed by them. Thus, improvement in regulatory scenario will positively impact regional market growth.

Latin America DTC Genetic Testing Market Size, By Country, 2025 (USD Million)

Key Players, Recent Developments & Sector Viewpoints: Direct-to-Consumer Genetic Testing Market

Few of the eminent industry players operating in direct-to-consumer genetic testing market are Ancestry, 23andMe, Color, Family Tree DNA, EasyDNA, Helix, Identigene, Full Genomes, Genesis HealthCare, Karmagenes, MyHeritage, MapMyGenome, Living DNA and Pathway Genomics. Chief industry players implement numerous initiatives such as mergers, acquisitions and new product launch to maintain their market position. Receiving approvals from regulatory bodies for new products will also foster companys revenue share. For instance, in October 2018, 23andme received first U.S. FDA approval for de novotechnology utilized in pharmacogenomic tests. This approval will enable company to launch innovative products, thereby fostering companys growth.

Direct-to-Consumer (DTC) Genetic Testing Industry Viewpoint

Direct-to-consumer genetic testing industry can be traced back to early 2000s. Earlier DTC tests were thought to be convenient as they would allow the patients to access their genetic information without involvement of physician. Although, DTC genetic testing kits had several benefits, in the initial days, they were stringently regulated by regulatory bodies. Regulatory scenario has always been stringent since the introduction of DTC genetic kits in European countries. Currently, there has been change in the regulatory scenario and European countries have started receiving approval for DTC genetic kits. Defects in the DTC kits have been reduced and people have started relying on these kits. DTC genetic testing market is sort of matured in North America due to numerous technological advancements and is still in developing phase in Asian countries. With further advancements in technology, DTC genetic tests industry will experience numerous growth opportunitie

Key Insights Covered: Exhaustive Direct-to-Consumer Genetic Testing Market1. Market size (sales, revenue and growth rate) of Direct-to-Consumer Genetic Testing industry.2. Global major manufacturers operating situation (sales, revenue, growth rate and gross margin) of Direct-to-Consumer Genetic Testing industry.3. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Direct-to-Consumer Genetic Testing industry.4. Market size (sales, revenue) forecast by regions and countries from 2019 to 2025 of Direct-to-Consumer Genetic Testing industry.

Research Methodology: Direct-to-Consumer Genetic Testing Market

Looking for more? Check out our repository for all available reports on Direct-to-Consumer Genetic Testing in related sectors.

Quick Read Table of Contents of this Report @ Direct-to-Consumer Genetic Testing Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

See original here:
Direct-to-Consumer Genetic Testing Market: Trends, Applications, Industry Competitive Analysis, Growth,Forecast: 2019 to 2029 - The Scarlet

Recommendation and review posted by Bethany Smith

SAN DIEGO, Aug. 28, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that on August 26, 2020, it commenced mailing an open letter to stockholders in support of its proposal to increase authorized shares, a copy of which is included at the end of this press release.

Erik Holmlin, PhD, CEO of Bionano commented, We are fast approaching our stockholder meeting to be held on August 31, 2020. I want to thank the many stockholders whose input helped craft the strategy we are pursuing to increase our authorized shares without an accompanying reverse stock split. This increase in authorized shares is imperative and has been carefully considered after receiving abundant stockholder feedback. As of August 26, 2020, we had approximately 13.3 million available authorized shares, which we continue to believe is insufficient to meet our needs for future financings and strategic transactions as well as incentivize our key personnel. For this reason, and as further detailed in the enclosed letter to stockholders and the proxy statement for the special meeting, we ask that you vote For the proposal. If you have voted against this proposal, we ask that you consider the Companys urgent need and vote For the proposal.

Details of the Special Meeting of StockholdersThe special meeting of stockholders will be held virtually, via live webcast at http://www.virtualshareholdermeeting.com/BNGO2020, on Monday, August 31, 2020, at 10:00 a.m. Pacific Time. Stockholders of record as of July 27, 2020, may vote at the special meeting or by proxy over the telephone, through the internet or using the proxy card included in the proxy materials mailed to such stockholders. Stockholders may change their vote at any time before the final vote at the special meeting.

Details regarding voting procedures are included in the Companys proxy statement for the special meeting, filed with the U.S. Securities Commission on August 3, 2020.

About Bionano GenomicsBionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business. Bionanos Saphyr system is a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools, and genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs. Lineagen has been providing genetic testing services to families and their healthcare providers for over nine years and has performed over 65,000 tests for those with neurodevelopmental concerns. For more information, visitwww.bionanogenomics.com or http://www.lineagen.com.

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as may, will, expect, plan, anticipate, estimate, intend and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the need for an increase in authorized shares of common stock from 200,000,000 shares to 400,000,000 shares and the potential negative impacts to the company if the corresponding proposal is not approved. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive products; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the loss of key members of management and our commercial team; and the risks and uncertainties associated withour business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2019 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

Letter to Stockholders

August 26, 2020

Dear Fellow Stockholder,

I am writing to ask for your support of the increase in authorized shares proposal (Proposal1) contained in the Definitive Proxy Statement for our Special Meeting of Stockholders to be held on August 31, 2020 at 10:00 a.m. Pacific Time. It is imperative for the future of the company that you, our stockholders, vote in favor of this proposal.

At the current level of authorized shares, Bionano Genomics is unable to confidently take the steps we feel are necessary to move the company forward in key strategic and financial areas. We believe the increase will enable us to, among other things, execute future potential equity financings, recruit and retain exceptional talent, and pursue potential strategic transactions.

I cannot emphasizeenough the importance of this share increase.

Without sufficient authorized shares, we believe that we will not be able to:

Therefore, I would again like to ask that you please support Proposal 1 as described in the Proxy Statement, which is for an increase in authorized shares without any reverse split component. We believe that doing so will give Bionano a much better chance of succeeding in its core mission.

Thank you.

Sincerely,

Erik HolmlinPresident and CEOBionano Genomics, Inc.

CONTACTSCompany Contact:Erik Holmlin, CEOBionano Genomics, Inc.+1 (858) 888-7610eholmlin@bionanogenomics.com

Investor Relations Contact:Ashley R. RobinsonLifeSci Advisors, LLC+1 (617) 430-7577arr@lifesciadvisors.com

Media Contact:Darren Opland, PhD+1 (617) 733-7668darren@lifescicomms.com

See more here:
Bionano Genomics Emphasizes the Importance of Supporting the Proxy Proposal to Increase its Authorized Shares - GlobeNewswire

Recommendation and review posted by Bethany Smith

The Direct-To-Consumer (DTC) Genetic Testing market research encompasses an exhaustive analysis of the market outlook, framework, and socio-economic impacts. The report covers the accurate investigation of the market size, share, product footprint, revenue, and progress rate. Driven by primary and secondary researches, the Direct-To-Consumer (DTC) Genetic Testing market study offers reliable and authentic projections regarding the technical jargon.

All the players running in the global Direct-To-Consumer (DTC) Genetic Testing market are elaborated thoroughly in the Direct-To-Consumer (DTC) Genetic Testing market report on the basis of proprietary technologies, distribution channels, industrial penetration, manufacturing processes, and revenue. In addition, the report examines R&D developments, legal policies, and strategies defining the competitiveness of the Direct-To-Consumer (DTC) Genetic Testing market players.

Request Sample Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2637644&source=atm

The key players covered in this studyAncestryColor GenomicsEasy DNAFamilytreeDNA (Gene By Gene)Full Genome CorporationHelix OpCo LLCIdentigeneKarmagenesLiving DNAMapmygenomeMyHeritagePathway GenomicsGenesis Healthcare23andMe

Market segment by Type, the product can be split intoCarrier TestingPredictive TestingAncestry & Relationship TestingNutrigenomics TestingOthersMarket segment by Application, split intoOnline PlatformsOver-the-Counter

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

The study objectives of this report are:To analyze global Direct-To-Consumer (DTC) Genetic Testing status, future forecast, growth opportunity, key market and key players.To present the Direct-To-Consumer (DTC) Genetic Testing development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Direct-To-Consumer (DTC) Genetic Testing are as follows:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year 2020 to 2026For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Make An EnquiryAbout This Report @ https://www.marketresearchhub.com/enquiry.php?type=E&repid=2637644&source=atm

Objectives of the Direct-To-Consumer (DTC) Genetic Testing Market Study:

The Direct-To-Consumer (DTC) Genetic Testing market research focuses on the market structure and various factors (positive and negative) affecting the growth of the market. The study encloses a precise evaluation of the Direct-To-Consumer (DTC) Genetic Testing market, including growth rate, current scenario, and volume inflation prospects, on the basis of DROT and Porters Five Forces analyses. In addition, the Direct-To-Consumer (DTC) Genetic Testing market study provides reliable and authentic projections regarding the technical jargon.

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2637644&licType=S&source=atm

After reading the Direct-To-Consumer (DTC) Genetic Testing market report, readers can:

Original post:
Direct-To-Consumer (DTC) Genetic Testing Market Future Need Assessment 2028 - The News Brok

Recommendation and review posted by Bethany Smith

Global Direct-To-Consumer (DTC) Genetic Testing Market 2020 Global Industry Research Report is deep analysis by historical and current status of the market/industries for Global Direct-To-Consumer (DTC) Genetic Testing industry. Also, research report categorizes the global Direct-To-Consumer (DTC) Genetic Testing market by Segment by Player, Type, Application, Marketing Channel, and Region. Direct-To-Consumer (DTC) Genetic Testing Market report also tracks the latest market dynamics, such as driving factors, restraining factors, and industry news like mergers, acquisitions, and investments. Direct-To-Consumer (DTC) Genetic Testing Market Research Report provides market size (value and volume), market share, growth rate by types, applications, and combines both qualitative and quantitative methods to make micro and macro forecasts.

Get a Sample PDF of report at https://www.researchreportsworld.com/enquiry/request-sample/15536587

The objective of the study is to define market sizes of different segments and countries in previous years and to forecast the values to the next Five years. The report is designed to incorporate both qualify qualitative and quantitative aspects of the industry with respect to each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as drivers and restraining factors which will define the future growth of the Direct-To-Consumer (DTC) Genetic Testing market.

To Understand How COVID-19 Impact is Covered in This Report. Get Sample copy of the report at https://www.researchreportsworld.com/enquiry/request-covid19/15536587

The research covers the current Direct-To-Consumer (DTC) Genetic Testing market size of the market and its growth rates based on 6-year records with company outline of Key players/manufacturers:

Get a Sample Copy of the Direct-To-Consumer (DTC) Genetic Testing Market Report 2020

Short Description about Direct-To-Consumer (DTC) Genetic Testing Market:

The report also focuses on global major leading industry players of Global Direct-To-Consumer (DTC) Genetic Testing market providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. This report focuses on Direct-To-Consumer (DTC) Genetic Testing Market Trend, volume and value at global level, regional level and company level. From a global perspective, this report represents overall Direct-To-Consumer (DTC) Genetic Testing Market Size by analyzing historical data and future prospect.

The global Direct-To-Consumer (DTC) Genetic Testing Market is anticipated to rise at a considerable rate during the forecast period, between 2020 and 2026. In 2020, the market was growing at a steady rate and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

The Direct-To-Consumer (DTC) Genetic Testing market is expected to grow at a Highest CAGR during the forecast period 2020-2026.

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including

Enquire before purchasing this report https://www.researchreportsworld.com/enquiry/pre-order-enquiry/15536587

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Direct-To-Consumer (DTC) Genetic Testing in these regions, from 2020 to 2026, covering

This Direct-To-Consumer (DTC) Genetic Testing Market Research/Analysis Report Contains Answers to your following Questions

Purchase this report (Price 3900 USD for single user license) https://www.researchreportsworld.com/purchase/15536587

Major Points from Table of Contents:

1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered: Ranking by Direct-To-Consumer (DTC) Genetic Testing Revenue1.4 Market Analysis by Type1.4.1 Global Direct-To-Consumer (DTC) Genetic Testing Market Size Growth Rate by Type: 2020 VS 20261.4.2 Carrier Testing1.4.3 Predictive Testing1.4.4 Ancestry & Relationship Testing1.4.5 Nutrigenomics Testing1.4.6 Others1.5 Market by Application1.5.1 Global Direct-To-Consumer (DTC) Genetic Testing Market Share by Application: 2020 VS 20261.5.2 Online Platforms1.5.3 Over-the-Counter1.6 Coronavirus Disease 2019 (Covid-19): Direct-To-Consumer (DTC) Genetic Testing Industry Impact1.6.1 How the Covid-19 is Affecting the Direct-To-Consumer (DTC) Genetic Testing Industry1.6.1.1 Direct-To-Consumer (DTC) Genetic Testing Business Impact Assessment Covid-191.6.1.2 Supply Chain Challenges1.6.1.3 COVID-19s Impact On Crude Oil and Refined Products1.6.2 Market Trends and Direct-To-Consumer (DTC) Genetic Testing Potential Opportunities in the COVID-19 Landscape1.6.3 Measures / Proposal against Covid-191.6.3.1 Government Measures to Combat Covid-19 Impact1.6.3.2 Proposal for Direct-To-Consumer (DTC) Genetic Testing Players to Combat Covid-19 Impact1.7 Study Objectives1.8 Years Considered

2 Global Growth Trends by Regions2.1 Direct-To-Consumer (DTC) Genetic Testing Market Perspective (2015-2026)2.2 Direct-To-Consumer (DTC) Genetic Testing Growth Trends by Regions2.2.1 Direct-To-Consumer (DTC) Genetic Testing Market Size by Regions: 2015 VS 2020 VS 20262.2.2 Direct-To-Consumer (DTC) Genetic Testing Historic Market Share by Regions (2015-2020)2.2.3 Direct-To-Consumer (DTC) Genetic Testing Forecasted Market Size by Regions (2021-2026)2.3 Industry Trends and Growth Strategy2.3.1 Market Top Trends2.3.2 Market Drivers2.3.3 Market Challenges2.3.4 Porters Five Forces Analysis2.3.5 Direct-To-Consumer (DTC) Genetic Testing Market Growth Strategy2.3.6 Primary Interviews with Key Direct-To-Consumer (DTC) Genetic Testing Players (Opinion Leaders)

3 Competition Landscape by Key Players3.1 Global Top Direct-To-Consumer (DTC) Genetic Testing Players by Market Size3.1.1 Global Top Direct-To-Consumer (DTC) Genetic Testing Players by Revenue (2015-2020)3.1.2 Global Direct-To-Consumer (DTC) Genetic Testing Revenue Market Share by Players (2015-2020)3.1.3 Global Direct-To-Consumer (DTC) Genetic Testing Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.2 Global Direct-To-Consumer (DTC) Genetic Testing Market Concentration Ratio3.2.1 Global Direct-To-Consumer (DTC) Genetic Testing Market Concentration Ratio (CR5 and HHI)3.2.2 Global Top 10 and Top 5 Companies by Direct-To-Consumer (DTC) Genetic Testing Revenue in 20193.3 Direct-To-Consumer (DTC) Genetic Testing Key Players Head office and Area Served3.4 Key Players Direct-To-Consumer (DTC) Genetic Testing Product Solution and Service3.5 Date of Enter into Direct-To-Consumer (DTC) Genetic Testing Market3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)4.1 Global Direct-To-Consumer (DTC) Genetic Testing Historic Market Size by Type (2015-2020)4.2 Global Direct-To-Consumer (DTC) Genetic Testing Forecasted Market Size by Type (2021-2026)

5 Direct-To-Consumer (DTC) Genetic Testing Breakdown Data by Application (2015-2026)5.1 Global Direct-To-Consumer (DTC) Genetic Testing Market Size by Application (2015-2020)5.2 Global Direct-To-Consumer (DTC) Genetic Testing Forecasted Market Size by Application (2021-2026)

6 North America6.1 North America Direct-To-Consumer (DTC) Genetic Testing Market Size (2015-2020)6.2 Direct-To-Consumer (DTC) Genetic Testing Key Players in North America (2019-2020)6.3 North America Direct-To-Consumer (DTC) Genetic Testing Market Size by Type (2015-2020)6.4 North America Direct-To-Consumer (DTC) Genetic Testing Market Size by Application (2015-2020)

7 Europe7.1 Europe Direct-To-Consumer (DTC) Genetic Testing Market Size (2015-2020)7.2 Direct-To-Consumer (DTC) Genetic Testing Key Players in Europe (2019-2020)7.3 Europe Direct-To-Consumer (DTC) Genetic Testing Market Size by Type (2015-2020)7.4 Europe Direct-To-Consumer (DTC) Genetic Testing Market Size by Application (2015-2020)

8 China8.1 China Direct-To-Consumer (DTC) Genetic Testing Market Size (2015-2020)8.2 Direct-To-Consumer (DTC) Genetic Testing Key Players in China (2019-2020)8.3 China Direct-To-Consumer (DTC) Genetic Testing Market Size by Type (2015-2020)8.4 China Direct-To-Consumer (DTC) Genetic Testing Market Size by Application (2015-2020)

9 Japan9.1 Japan Direct-To-Consumer (DTC) Genetic Testing Market Size (2015-2020)9.2 Direct-To-Consumer (DTC) Genetic Testing Key Players in Japan (2019-2020)9.3 Japan Direct-To-Consumer (DTC) Genetic Testing Market Size by Type (2015-2020)9.4 Japan Direct-To-Consumer (DTC) Genetic Testing Market Size by Application (2015-2020)

10 Southeast Asia10.1 Southeast Asia Direct-To-Consumer (DTC) Genetic Testing Market Size (2015-2020)10.2 Direct-To-Consumer (DTC) Genetic Testing Key Players in Southeast Asia (2019-2020)10.3 Southeast Asia Direct-To-Consumer (DTC) Genetic Testing Market Size by Type (2015-2020)10.4 Southeast Asia Direct-To-Consumer (DTC) Genetic Testing Market Size by Application (2015-2020)

11 India11.1 India Direct-To-Consumer (DTC) Genetic Testing Market Size (2015-2020)11.2 Direct-To-Consumer (DTC) Genetic Testing Key Players in India (2019-2020)11.3 India Direct-To-Consumer (DTC) Genetic Testing Market Size by Type (2015-2020)11.4 India Direct-To-Consumer (DTC) Genetic Testing Market Size by Application (2015-2020)

12 Central & South America12.1 Central & South America Direct-To-Consumer (DTC) Genetic Testing Market Size (2015-2020)12.2 Direct-To-Consumer (DTC) Genetic Testing Key Players in Central & South America (2019-2020)12.3 Central & South America Direct-To-Consumer (DTC) Genetic Testing Market Size by Type (2015-2020)12.4 Central & South America Direct-To-Consumer (DTC) Genetic Testing Market Size by Application (2015-2020)

13Key Players Profiles13.1 Ancestry13.1.1 Ancestry Company Details13.1.2 Ancestry Business Overview and Its Total Revenue13.1.3 Ancestry Direct-To-Consumer (DTC) Genetic Testing Introduction13.1.4 Ancestry Revenue in Direct-To-Consumer (DTC) Genetic Testing Business (2015-2020))13.1.5 Ancestry Recent Development13.2 Color Genomics13.2.1 Color Genomics Company Details13.2.2 Color Genomics Business Overview and Its Total Revenue13.2.3 Color Genomics Direct-To-Consumer (DTC) Genetic Testing Introduction13.2.4 Color Genomics Revenue in Direct-To-Consumer (DTC) Genetic Testing Business (2015-2020)13.2.5 Color Genomics Recent Development13.3 Easy DNA13.3.1 Easy DNA Company Details13.3.2 Easy DNA Business Overview and Its Total Revenue13.3.3 Easy DNA Direct-To-Consumer (DTC) Genetic Testing Introduction13.3.4 Easy DNA Revenue in Direct-To-Consumer (DTC) Genetic Testing Business (2015-2020)13.3.5 Easy DNA Recent Development13.4 FamilytreeDNA (Gene By Gene)13.4.1 FamilytreeDNA (Gene By Gene) Company Details13.4.2 FamilytreeDNA (Gene By Gene) Business Overview and Its Total Revenue13.4.3 FamilytreeDNA (Gene By Gene) Direct-To-Consumer (DTC) Genetic Testing Introduction13.4.4 FamilytreeDNA (Gene By Gene) Revenue in Direct-To-Consumer (DTC) Genetic Testing Business (2015-2020)13.4.5 FamilytreeDNA (Gene By Gene) Recent Development13.5 Full Genome Corporation13.5.1 Full Genome Corporation Company Details13.5.2 Full Genome Corporation Business Overview and Its Total Revenue13.5.3 Full Genome Corporation Direct-To-Consumer (DTC) Genetic Testing Introduction13.5.4 Full Genome Corporation Revenue in Direct-To-Consumer (DTC) Genetic Testing Business (2015-2020)13.5.5 Full Genome Corporation Recent Development13.6 Helix OpCo LLC13.6.1 Helix OpCo LLC Company Details13.6.2 Helix OpCo LLC Business Overview and Its Total Revenue13.6.3 Helix OpCo LLC Direct-To-Consumer (DTC) Genetic Testing Introduction13.6.4 Helix OpCo LLC Revenue in Direct-To-Consumer (DTC) Genetic Testing Business (2015-2020)13.6.5 Helix OpCo LLC Recent Development13.7 Identigene13.7.1 Identigene Company Details13.7.2 Identigene Business Overview and Its Total Revenue13.7.3 Identigene Direct-To-Consumer (DTC) Genetic Testing Introduction13.7.4 Identigene Revenue in Direct-To-Consumer (DTC) Genetic Testing Business (2015-2020)13.7.5 Identigene Recent Development13.8 Karmagenes13.8.1 Karmagenes Company Details13.8.2 Karmagenes Business Overview and Its Total Revenue13.8.3 Karmagenes Direct-To-Consumer (DTC) Genetic Testing Introduction13.8.4 Karmagenes Revenue in Direct-To-Consumer (DTC) Genetic Testing Business (2015-2020)13.8.5 Karmagenes Recent Development13.9 Living DNA13.9.1 Living DNA Company Details13.9.2 Living DNA Business Overview and Its Total Revenue13.9.3 Living DNA Direct-To-Consumer (DTC) Genetic Testing Introduction13.9.4 Living DNA Revenue in Direct-To-Consumer (DTC) Genetic Testing Business (2015-2020)13.9.5 Living DNA Recent Development13.10 Mapmygenome13.10.1 Mapmygenome Company Details13.10.2 Mapmygenome Business Overview and Its Total Revenue13.10.3 Mapmygenome Direct-To-Consumer (DTC) Genetic Testing Introduction13.10.4 Mapmygenome Revenue in Direct-To-Consumer (DTC) Genetic Testing Business (2015-2020)13.10.5 Mapmygenome Recent Development13.11 MyHeritage10.11.1 MyHeritage Company Details10.11.2 MyHeritage Business Overview and Its Total Revenue10.11.3 MyHeritage Direct-To-Consumer (DTC) Genetic Testing Introduction10.11.4 MyHeritage Revenue in Direct-To-Consumer (DTC) Genetic Testing Business (2015-2020)10.11.5 MyHeritage Recent Development13.12 Pathway Genomics10.12.1 Pathway Genomics Company Details10.12.2 Pathway Genomics Business Overview and Its Total Revenue10.12.3 Pathway Genomics Direct-To-Consumer (DTC) Genetic Testing Introduction10.12.4 Pathway Genomics Revenue in Direct-To-Consumer (DTC) Genetic Testing Business (2015-2020)10.12.5 Pathway Genomics Recent Development13.13 Genesis Healthcare10.13.1 Genesis Healthcare Company Details10.13.2 Genesis Healthcare Business Overview and Its Total Revenue10.13.3 Genesis Healthcare Direct-To-Consumer (DTC) Genetic Testing Introduction10.13.4 Genesis Healthcare Revenue in Direct-To-Consumer (DTC) Genetic Testing Business (2015-2020)10.13.5 Genesis Healthcare Recent Development13.14 23andMe10.14.1 23andMe Company Details10.14.2 23andMe Business Overview and Its Total Revenue10.14.3 23andMe Direct-To-Consumer (DTC) Genetic Testing Introduction10.14.4 23andMe Revenue in Direct-To-Consumer (DTC) Genetic Testing Business (2015-2020)10.14.5 23andMe Recent Development

14Analysts Viewpoints/Conclusions

15Appendix15.1 Research Methodology15.1.1 Methodology/Research Approach15.1.2 Data Source15.2 Disclaimer15.3 Author Details

Continued..

Browse complete table of contents at

https://www.researchreportsworld.com/TOC/15536587

About Us:

Research Reports World is the credible source for gaining the market reports that will provide you with the lead your business needs. At Research Reports World, our objective is providing a platform for many top-notch market research firms worldwide to publish their research reports, as well as helping the decision makers in finding most suitable market research solutions under one roof. Our aim is to provide the best solution that matches the exact customer requirements. This drives us to provide you with custom or syndicated research reports.

CONTACT US

Name: Ajay More

Email:[emailprotected]

Phone:US +1 424 253 0807 /UK +44 203 239 8187

Other Reports Here:

Clean Room Oven Market 2020 Global Industry Size, Share, Analysis, Development, Revenue, Future Growth, Business Prospects and Forecast to 2025 Research Reports World

Diabetes Therapeutics and Diagnostics Market Share, Size, 2020 Industry Growth, Business Revenue, Future Plans, Top Key Players, Business Opportunities, Global Size Analysis by Forecast to 2025 Research Reports World

Retro-Reflective Materials Market Size, share 2020 Global Industry Trends, Growth Drivers, Demands, Business Opportunities and Demand Forecast to 2026

Vinylon Fiber Market 2020 Global Industry Analysis by Growth, Key Players, Share, Revenue, Trends, Organizations Size, Opportunities, And Regional Forecast to 2026

Stretch Training Machines Market Growth 2020 Global Industry Size, Analysis, Share, Trends, Market Demand, Growth, Opportunities and Forecast 2025

Beach Cruiser Bikes Market 2020 Size, Share, Global Trends, Comprehensive Research Study, Development Status, Opportunities, Future Plans, Competitive Landscape and Growth by Forecast 2025

Go here to see the original:
Direct-To-Consumer (DTC) Genetic Testing Market 2020 Global Industry Size, Recent Trends, Demand and Share Estimation by 2026 with Top Players...

Recommendation and review posted by Bethany Smith

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

The Direct-to-Consumer Genetic Testing Devices market demand is anticipated to flourish during the forecast period 2018-2026. The report offers information related to import and export, along with the current business chain in the market at the global level. This report provides an in-depth overview of the Direct-to-Consumer Genetic Testing Devices market. This includes market characteristics, consisting of segmentation, market share, trends and strategies for this market. The Market Size section provides historical forecasts of market growth and future. An in-depth analysis of the major companies operating in the market is also mentioned in this research report.

Get FREE PDF Brochure Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/1046

The global Direct-to-Consumer Genetic Testing Devices market is segmented on the basis of type and application.

It also provides market size and forecast estimates from the year 2018 to 2026 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East & Africa (MEA), and South America (SAM). The Direct-to-Consumer Genetic Testing Devices market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of top countries globally along with the current trend and opportunities prevailing in the region.

A thorough examination of the Direct-to-Consumer Genetic Testing Devices market includes each and every aspect, which begins with knowing the market, speaking with clients, and evaluating the complete data of the global market. For more clarification, the global market is segmented on the basis of the manufacture of the kind of products, and their applications. The report also delivers information as per the regions based on the geographical classification of the global Direct-to-Consumer Genetic Testing Devices market. The dynamic foundation of the global market is based on the calculation of product supply in different markets, their revenues, capability, and a chain of production.

Qualitative information will discuss the key factors driving the restraining the growth of the market, and the possible growth opportunities of the market, regulatory scenario, value chain & supply chain analysis, export & import analysis, attractive investment proposition, and Porters 5 Forces analysis among others will be a part of qualitative information.

Competitive Section

Key players operating the Direct-to-Consumer Genetic Testing Devices market are Pathway Genomics, Color Genomics, Counsyl, Inc., deCode genetics, Inc., Map My Gene, and GenePartner.

Furthermore, this study will help our clients solve the following issues:

Market dynamics- The study foresees dynamics of industries by using core analytical and unconventional market research approaches. This will help clients to use this insight provided to maneuver themselves through market uncertainties and disruptions

Identifying key cannibalizes Strong substitute for a product or service is the most prominent threat. Our clients can identify key cannibalizes of a market, by procuring our research. This helps them in aligning their new product development/launch strategies in advance

Spotting emerging trends-Our Ecosystem offering helps clients to spot upcoming hot market trends. We also track possible impact and disruptions which a market would witness by a particular emerging trend. Our proactive analysis helps clients to have early mover advantage

Interrelated opportunities- This report will allow clients to make decisions based on data, thereby increasing the chances that the strategies will perform better if not best in the real world

Apply Promo Code CMIFIRST1000 And Get Instant Discount Of USD 1000Quick [emailprotected] https://www.coherentmarketinsights.com/insight/buy-now/1046

All in all, the Direct-to-Consumer Genetic Testing Devices market research study elucidates a detailed evaluation of this business and projects this industry to register a commendable growth rate in the forthcoming years. The Direct-to-Consumer Genetic Testing Devices market analysis report also delivers important insights with respect to aspects such as the volume of sales, valuation forecast, market size, and the market competition trends as well as the market concentration rate.

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website http://www.coherentmarketinsights.com

Contact:

Coherent Market Insights1001 4th Ave, #3200 Seattle, WA 98154, U.S.Email: [emailprotected]United States of America: +1-206-701-6702United Kingdom: +44-020-8133-4027Japan: +050-5539-1737India: +91-848-285-0837

See the article here:
Direct-to-Consumer Genetic Testing Devices Market Forecast 2026 By Industry Size and Share, Demand, Worldwide Research, Prominent Players, Emerging...

Recommendation and review posted by Bethany Smith

A TEENAGE boy has been warned he could become entombed in his own body as he battles a rare skin condition.

Jaiden Rogers has Stiff Skin Syndrome, a disease which causes the skin to harden.

7

His Mum Natalie says he is turning to stone due to the condition that has left the 15-year-old confined to a wheelchair and at risk of organ failure as his stone-like skin presses on his lungs and heart.

Jaiden was diagnosed with the condition in 2013 after mum Natalie, 54, found a lump of hard skin on his thigh.

It soon spread to his arms, legs, stomach and neck.

Natalie, who is a stay-at-home mum, said: "Jaiden is basically turning to stone and it's become so hard that he can't really move his legs.

"If he doesn't get treatment, doctors say he'll become entombed in his own body.

"His whole body is turning to stone because this disease starts from the inside and works it way to the skin.

Once it reaches his skin, it means all his body underneath is also hard like stone."

7

7

She said the skin has now started to compress on his heart - leaving him unable to breath without a ventilator.

It's pressing on the other organs so they will start failing.

"His future doesn't look good."

Natalie and her husband Tim, 56, are now raising funds to pay for Jaiden to get to Italy where he will be able to receive treatment which will help stop the disease before it crushes his lungs.

The mum-of-three, from Colorado, US, said: "If we don't get him to Italy, he won't live.

7

What is Stiff skin syndrome (SSS)

Stiff skin syndrome is a rare skin condition and is characterised by hard, thick skin on the body.

The thickening of the skin can make the sufferer immobile and can cause joints to get stuck in a bent position.

It is caused by a gene mutation.

What are the signs?

The condition will often present at birth or in childhood and symptoms include:

"Once he has treatment to stop the progression of the disease, he'll be able to have therapy to help loosen the skin.

"The doctors think he's the only one in the world with the condition and there's only been 41 documented cases in the world.

"It started when we found a hard spot on his thigh.

She said that at first, no one really thought anything of it.

We took him to the doctors and after some tests, the doctor called me and told me to sit down.

"That isn't what you want to hear from a doctor.

7

7

"I'd never heard of the condition before and most doctors haven't heard of it so I didn't think much of it until they continued telling me what it would do.

"Within three months it had really started spreading down his leg and he needed a wheelchair.

"It was horrible and he was in severe pain."

Before being diagnosed Jaiden loved to play football.

Now the teen is destined to spend the rest of his life in a wheelchair despite taking chemotherapy medication to help slow down the spread of the disease.

7

Jaiden has also had to drop out of school and is currently being taught at home by his parents.

Natalie said: "He's very quiet about it, he doesn't like talking about it but he cries because it hurts.

"He used to love going to the park and playing soccer and he's obsessed with Ed Sheeran.

Exclusive

TOTTING UPI got 2,450 of baby clothes for 100 including a 644 pram for a TENNER

OH BABYTop 20 'most endangered' names at risk of disappearing - including Kirsty & Kieran

CRUSHED ITWoman wanted 360 crushed diamond table so made one using The Range coasters

NO KIDDINGMum bags 30 food shop for 3 after struggling to make ends meet before payday

Exclusive

BRIGHT ONI spent 2.5k & 4 years transforming this boring beige home into my own paradise

BUBBLE TROUBLECleaning fan regrets washing his trainers in Vanish after rainy walk

"He was so active, he was all over the place like any other kid but now he sleeps most of the day because of the pain killers he's on.

"This disease has caused him to have no friends because he is in so much pain.

"He'll always be in a wheelchair and we can't change that but we need to get him to Italy so we can at least prolong his life.

"Basically, if we don't get him there, he won't live."

See original here:
Our teenage son is turning to stone and is becoming entombed in his own body - The Sun

Recommendation and review posted by Bethany Smith

Feeling stressed out and exhausted? You might be tempted to blame the infamous stress hormone known as cortisol.

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services.Policy

Theres a lot of information and theories about cortisol floating around. For instance: You can lower cortisol levels with a nice cup of tea or even better chocolate.

Alas, its not quite that simple. (Is it ever?) Nutrition is absolutely important for coping with stress and supporting your mood, but theres no single food thats going to do it all, says integrative medicine doctor Yufang Lin, MD. You have to look at the whole lifestyle picture.

Taking everything like that into account is more important than ever right now as we deal not just with the stress from the ongoing coronavirus pandemic, but the emotional ups and downs that come with it.

Heres her big-picture advice for keeping cortisol and the rest of your body and mind in balance.

Cortisol is one of several hormones the body produces naturally. Cortisol levels do go up when youre stressed. But it doesnt deserve its bad rap.

Cortisol supports overall health, Dr. Lin says. It helps us wake up, gives us energy during the day and lowers at night to help us sleep and rest.

The problem arises when chronic stress keeps cortisol levels high for the long haul. High cortisol levels over weeks or months can lead to inflammation and a host of mental and physical health problems, from anxiety to weight gain to heart disease.

Yes, no and maybe. Some research suggests that foods like tea, chocolate and fish oils might lower cortisol. But such studies tend to be small and not very conclusive, Dr. Lin says.

Youre unlikely to balance cortisol levels by adding anchovies to your pizza or scarfing a block of chocolate, she says. But good nutrition can make a difference.

Cortisol interacts with neurotransmitters, the chemical messengers that send signals in the brain. Neurotransmitters play an important role in mood. And cortisol isnt the only compound that influences them. To make those neurotransmitters, you need all the raw ingredients: vitamins, minerals and other nutrients, Dr. Lin says.

The best way to get them is with a balanced, plant-heavy diet, such as the Mediterranean diet, she adds. A healthy diet is the underpinning of stress management.

A balanced meal plan can ensure youre getting the nutrients your body needs. And talk to your doctor about taking a basic multivitamin. Its a good insurance policy to make sure youre not deficient in any vitamins, Dr. Lin says.

The supplement aisle at the natural foods store is hardly a one-way ticket to a stress-free life. But some items may help keep cortisol levels in a healthy range, Dr. Lin says. Research suggests these herbs and natural supplements might lower stress, anxiety and/or cortisol levels:

While some herbs might help lower cortisol levels naturally, you dont want to swallow everything in sight, Dr. Lin says. Teas like lemon balm and chamomile are quite safe. But if youre thinking about trying herbs in supplement form, talk to a trained provider first.

Dr. Lin stresses that a big-picture approach is key to maintaining healthy cortisol levels and feeling less stressed. These go-to strategies are good for the body and the mind.

Exercise benefits health from head to toe. So its no surprise that it helps with stress relief, too, possibly by reducing cortisol levels. Studies show, for instance, that exercise can bring down cortisol levels in the elderly and in people with major depressive disorder.

Almost nothing beats a good nights sleep. When youre not sleeping well, you tend to be more anxious, irritable and stressed, Dr. Lin says. Like exercise, sleep is important for health in all sorts of ways including managing stress and keeping cortisol in check.

Sleep deprivation may increase cortisol levels. The increased cortisol can impair memory, contribute to weight gain and even accelerate the aging process. In other words: Dont skimp on shut-eye.

Spending time in the great outdoors is a great way to lower cortisol and calm your brain. The practice of forest bathing essentially, hanging out in the woods and breathing the forest air can reduce cortisol levels and lower stress. (Just pack your bug spray, so the mosquitoes dont stress you out.)

While they might not be something youve ever considered, practices like yoga, tai chi, qi gong, mindfulness meditation and breathing exercises can be great stress busters and a lot of skeptics have turned to converts. Research has found, for example, that mindfulness-based stress reduction therapy can lower cortisol and feelings of stress. And yoga can bring down high cortisol levels, heart rate and blood pressure.

When it comes to de-stressing, cortisol is just one piece of the puzzle, Dr. Lin adds. No one food or pill can deliver you to blissful calm. But healthy choices can set your body up for low-stress success.

Link:
How to Reduce Cortisol and Turn Down the Dial on Stress - Health Essentials from Cleveland Clinic

Recommendation and review posted by Bethany Smith

While Michigan Gov. Gretchen Whitmer has required people to wear face masks in public places to prevent spread of the COVID-19 virus, for some people face coverings can provoke anxiety.

Anything covering your nose and mouth sometimes can trick your body into feeling that the flow of oxygen to your brain is impeded, as if you might drown. That feeling can increase your bodys production of cortisol, the so-called fight or flight hormone, which raises your blood pressure and increases your breathing, heart rate, perspiration and anxiety level to prepare you to take action.

In a situation of real danger, this hormone response can save your life. But in chronic anxiety, it takes a toll on your health. According to the Mayo Clinic, The long-term activation of the stress-response system and the overexposure to cortisol and other stress hormones that follows can disrupt almost all your body's processes. This puts you at increased risk of many health problems, including:

Anxiety

Depression

Digestive problems

Headaches

Heart disease

Sleep problems

Weight gain

Memory and concentration impairment.

Therapists at the Birmingham Maple Clinic in Troy, who are seeing mask-related anxiety in some patients, have developed steps to help people cope with this anxiety and to feel more comfortable wearing masks. Carrie Krawiec is one of more than 30 therapists and psychiatrists who treat a variety of mental health issues at the clinic. She specializes in couples therapy, fertility and family issues.

Krawiec explains that during this coronavirus pandemic, most people feel a heightened sense of uncertainty and general anxiety, which means their bodies are a little tense, and they may be more prone to feeling panicky. The area of the face covered by masks is sensitive to heat, and those who suffer from anxiety may take a facial temperature increase as a threat.

Our bodies respond to cues like excess heat, shortness of breath or a change in heart rate as signs of possible danger, triggering the fight-or-flight response, which can cause us to hyperventilate or panic.

Dont panic!

The first step to overcoming anxiety, Krawiec suggests, is to understand that anxiety is normal right now, and theres nothing wrong with feeling anxious. Remind yourself that youre OK that theres nothing actually physically wrong with you.

Additionally, she says, predict circumstances that might make you anxious before you go out, then plan solutions for those situations before you get stressed out.

If wearing a mask in public is emotionally difficult for you, Krawiec says, try doing shorter errands to reduce the time you must spend wearing a mask. Prepare with a list and plan your trips to the grocery store so you dont have to search the aisles for things you need, further increasing anxiety.

If you're prone to panic, do errands early in the morning when its cooler, or later in the evening, so you wont feel overheated.

If youre out somewhere wearing your mask and you begin to feel uncomfortable, remember that its OK to leave the event or take a break away from other people to spend some time out of your mask.

Allow yourself permission to say, If I go and I become uncomfortable, I'm going to duck out, and have that be OK, Krawiec says.

More here:
Birmingham therapist discusses ways to overcome mask-related anxiety - The Oakland Press

Recommendation and review posted by Bethany Smith

Mayo Clinic News Network

Women with a history of high blood pressure disorders during pregnancy are more likely to experience bothersome menopausal symptoms such as hot flashes and night sweats, according to a study published in Menopause: The Journal of the North American Menopause Society.

We already know that women with high blood pressure during pregnancy or those who experience menopause symptoms such as hot flashes and night sweats have a higher risk of developing heart disease, said Dr. Stephanie Faubion, the studys lead author. Our research discovered that women who experienced high blood pressure during pregnancy were much more likely to experience bothersome menopausal symptoms, including hot flashes and night sweats during menopause.

Researchers analyzed the medical records of 2,684 women ages 40 to 65 who were seen for specialty menopause or sexual health consultations at womens health clinics at Mayo Clinic in Rochester, Minnesota, and Mayo Clinic in Scottsdale, Arizona, between May 2015 and September 2019. All study participants completed a questionnaire in which they self-reported their menopause symptoms and effects of these symptoms on their quality of life. Study participants also completed questionnaires that documented whether they experienced high blood pressure disorders during pregnancy, such as preeclampsia or gestational hypertension.

Faubion said more research is needed to understand why there is a link between high blood pressure disorders during pregnancy and more severe menopausal symptoms. But one thing is clear: Physicians need to do a better job monitoring women who experience high blood pressuring during pregnancy after they give birth.

Researchers discovered a significant association between women with a history of high blood pressure disorders during pregnancy who reported more bothersome menopausal symptoms. Women with this high blood pressure history using hormone therapy also reported more menopausal symptoms, compared to women with no history of high blood pressure disorders during pregnancy.

Faubion said more research is needed to understand why there is a link between high blood pressure disorders during pregnancy and more severe menopausal symptoms. But one thing is clear: Physicians need to do a better job monitoring women who experience high blood pressuring during pregnancy after they give birth.

We know medical providers have historically done a lousy job identifying and following women with histories of high blood pressure disorders during pregnancy, despite knowing that they have a higher heart disease risk, Faubion said. This study is another reminder that these women are different. It is important that they not only receive education with regard to what they may experience during menopause, but also that they undergo routine screenings and counseling on how they can reduce their risk for heart disease.

Continue reading here:
Study links high blood pressure in pregnancy and hot flashes - The Daily Herald

Recommendation and review posted by Bethany Smith

Authors note: This is not MY personal story, per se, (despite the my pandemic pregnancy headline), but a story told by our readers, week by week. Todays is shared by Hillary, from The Woodlands, Texas.

You might have heard that being pregnant, trying to get pregnant, or delivering right about now is strange, in this age of coronavirus. But how? In what ways? Were going to tell you. To contribute your own experience, scroll all the way down to the bottom of this article and tap the link.

When Hillary Calhouns fertility doctor brought her in for a procedure and then a nurse called her just a few short days later, asking her to come into the office immediately, the now-36-year-old had a hunch something wasnt right.

Hillarys husband, Bobby Calhoun, was out of town for work, so he couldnt accompany her to the appointment, but Hillary headed to the Houston-area clinic anyway, holding her breath a little, so to speak. The couple had been trying to get pregnant for years. Bobby had even gone under the knife as doctors reversed his vasectomy, which happened about 3 to four years ago, Hillary said in a phone call last week.

But back to Hillarys appointment. It was April 2019, and Hillary was in the office to learn about the results from her procedure. The previous Friday, doctors had performed a hysteroscopy, which is when they take a look at the uterus. A camera, of sorts, goes up the cervix, and specialists can then examine the fallopian tubes, ovaries and womb. Hillary waited and waited for the bottom line.

(The doctor) kept using the word abnormalities -- and he went on and on without really saying it, Hillary said.

After battling infertility for years, Hillary was aching to know what it was.

Then the doctor showed her the test results on a computer, and Hillary spotted the word carcinoma. Shes had family members whove experienced cancer, so she was familiar with some of the terminology. She knew that word.

Finally, Hillary said something to the effect of, OK, so I have cancer?

The doctor confirmed: That appeared to be the case. He told Hillary he thought the cancer looked to be in its early stages, but she would have to go through some more tests. The cancer, Hillary learned, was endometrial.

It was like, within one moment, someone took my dream away to have a baby, Hillary recalls thinking.

As soon as she could, she called Bobby, who was still in North Carolina on business, and she broke the news to him over the phone. Bobby was up on a roof at the time, and he got down and sped to the airport to be by Hillarys side.

The couple has been married about seven years. Bobby is a wonderful husband, Hillary said. He was incredibly supportive through this stressful time.

Hillary then made an appointment with a gynecological oncologist, who confirmed the cancer, ordered more tests and recommended a hysterectomy. The doctor said she believed this was a serious and life-threatening situation. A hysterectomy is an operation to remove a womans uterus entirely. But Hillary wanted to pause before making any major decisions.

Now, Im not trying to be reckless with my own life, but I thought it was early, said Hillary, adding that the doctor did confirm that the cancer appeared to be stage one.

I wanted to preserve my fertility, Hillary said.

While Bobby has four children (who are now a little older) from a previous marriage, Hillary still dreamed of becoming a mother. So she examined her options and asked about the possibility of hormone therapy. Her doctor agreed -- she could give it a shot.

Six months after starting, Hillary was cancer-free. It worked.

And then in October 2019, she went straight from cancer treatment to in vitro fertilization. It was a whirlwind.

Before they knew it, January arrived, and the couple learned they were pregnant. It worked.

It was unbelievable news, Hillary said.

To rewind a bit, the Calhouns werent always sure a baby would be possible.

Between Bobbys vasectomy and Hillarys history of endometriosis, polycystic ovary syndrome and uterine fibroids, she said, she had been told by doctors over the years that pregnancy might not be in the cards for her.

Shed tried the infertility drug Clomid to no avail.

And at some point, she started to fear that the doctors might be right.

I thought Id have to kiss that (pregnancy) dream goodbye, Hillary said.

But the couple thought it was worth it to fully explore the possibility. It was Bobby, after all, who was inspired and motivated to go for it.

I just kept thinking, if Gods going to put it on my husbands heart, there has to be a reason, Hillary said.

Cancer, Hillary said, turned out to be a blessing in disguise.

She had been experiencing some unexplained health issues, and her yearly or bi-yearly exams werent showing anything out of the ordinary.

But a Pap smear only tests for cervical cancer, not uterine cancer, Hillary said.

If I hadnt had infertility, I wouldnt have known, she told us. It was better than being diagnosed later, like when I had an infant. It happened exactly how it was supposed to, and this is how it was supposed to be.

Hillary has clarity and confidence about this. You can hear it in her voice. Shes also incredibly warm, chatty, open and ready for this miracle baby.

By waking up every morning and being grateful for the small things, it keeps you from getting frustrated from not being able to do all the things were used to doing, she said.

And thats not to say the ongoing pandemic has been easy on the couple.

Hillary was a few months into her pregnancy when COVID-19 hit. She and Bobby agreed: With so many unknowns, shed essentially go on lockdown mode. It seemed to be the safest option. Luckily, Hillary was able to work from home, for the most part.

Its just one of those things where you adapt because you have to, Hillary said. You survive because you have to. You cant let the fear consume you.

Still, she didnt shy away from addressing the sad parts. It feels strange that Bobby hasnt even met her doctor. Their doula, as it stands now, wont be able to attend the birth.

The couple even went through a bit of a scare at 20 weeks -- a bad bleed, as Hillary describes it -- and she had to take an ambulance to the emergency room.

Policies at their medical facility were strict. At first, hospital officials wouldnt even let Bobby in the door. Although he was eventually permitted into labor and delivery, where doctors were treating Hillary, he was told he couldnt leave the couples room -- not even to get a Coke, Hillary said.

The baby, by the way, is a girl. She and Hillary are doing just fine these days, despite a hot Texas summer. Olivia Grace is due Oct. 2. Her name has been picked out for a while now. Its almost like shes here already, the way Hillary talks about her and refers to her so effortlessly as Olivia. This is the little girl she was destined to have.

As far as labor and delivery are concerned, the plan for now is to labor at home with the doula for as long as possible. When Hillary arrives at the hospital, shes told shell have to wear a mask throughout labor. It sounds hard, but shes been rolling with the punches.

Ive had to learn to be a lot more open, Hillary said. With coronavirus, its easy to let fear consume you. And that could affect the delivery. So I want to avoid that as much as possible. I (have to) just go with the flow.

For a couple who doubted at some point that theyd ever get to this stage of life, it sounds like theyre doing a lot of stopping, taking in their surroundings and appreciating the beauty all around them.

(This surreal time) is a lot more intentional than normal life, which can be like, go go go go! Hillary said. To slow down has been really healthy for my pregnancy. Olivia was meant to be born in this time. There was a reason for it. Ill find out someday.

Originally posted here:
My pandemic pregnancy: From infertility to cancer to IVF to a 20-week scare: It happened exactly how it was supposed to' - WSLS 10

Recommendation and review posted by Bethany Smith

Kelly Osbournes secret to weight loss success was a vegan diet and intermittent fasting but it turns out there is more to the story, as Osbourne revealed on a podcast. The 35-year-old entertainment personality said that she kickstarted her weight loss journey with gastric sleeve surgery two years ago.

Osbourne appeared on Dax Holts podcast, Hollywood Raw, alongside comedian Adam Glyn, where she opened up about her weight loss surgery which is less drastic than gastric bypass but is used by doctors to help patients lose stubborn weight. Osbourne said:

I dont give a f**k what anyone has to say. I did it, Im proud of it, they can suck s**t. [I did] gastric sleeve," she continues: "All it does is change the shape of your stomach. I got that almost two years ago. I will never, ever, ever lie about it ever. It is the best thing I have ever done.

Gastric sleeve surgeries are less invasive than gastric bypass procedures. Gastric sleeve surgery helps weight loss by reducing the size of the stomach, according to the Mayo Clinic, and that in turn decreases appetite and helps you feel fuller for longer. It also reduces the amount of "hunger hormone" produced by the stomach, which may contribute to weight loss after this procedure.

Osbourne doesnt regret the choice to have surgery and encourages people to think it through and make sure its right for you since after surgery you need to be committed to healthier habits to see results. Osbourne admits she had to do a total overhaul of her eating habits and workout routine. If you dont work out and you dont eat right, you gain weight, Osbourne explained. All it does is move you in the right direction. So, anyone whos thinking of doing something like this, really think about that, since the surgery is no substitute for eating healthier and working out.

Before she could even fully commit to surgery, Osbourne said that she went through therapy to ensure it wouldnt derail her sobriety. I had to do a year of stand-alone therapy to prepare myself for the surgery before I even had it, she explained. What people dont realize is it cuts out this hormone that if you have addiction issues, it stops your craving, and it makes you not emotionally eat, which is a huge problem for me."

All the work she did on herself pre and post-surgery only helped her get the weight off, 85 pounds in all, and shut down her cravings. "I was sober before, [and] it did help, I dont crave alcohol at all anymore. All [the surgery] is is a push in the right direction. It doesnt solve all your problems. Its not a quick fix.

To Kellys surprise, people started to speculate that she had used surgery to help her with her weight loss journey. In fact, the thing they remarked on was her jawline, but that was related to having another condition, called TMJ, or Temporomandibular joint dysfunction.

I had a really bad TMJ (pain and lack of movement in the jaw) ... One of the things they did to stop it was they gave me injections in my jaw. It kinda made my jaw look skinnier. Thats when people started to notice that I had really lost weight because it changed the shape of everything, Osbourne explained. ... I found out Its called buckle fat. It changed everything on my face! Why the f--k didn't I know about this sooner?"

Osbourne couldnt believe the attention she received after one Instagram that showed off her weight loss. I woke up one day and I was all over the newspapers and sites. I had literally hundreds of text messages. I got asked out seven times in one day. I said no thanks to every single one of them, she explained.

Osbournes surgery isnt the only thing that helped her get the weight off. Years of hard work and eating healthy also play a huge role, including her vegan and her daily workout routines. Osbourne says that her vegan diet has helped her remain sober and stay the course on her weight loss journey. She also uses intermittent fasting to lose weight and keep it off. Kellys newfound passion for fitness and her daily workout routine is also what helped keep her on track throughout quarantine. Osbourne says she is the healthiest and happiest shes been in a long time and her gastric surgery helped kickstart that journey

Read more:
Kelly Osbourne's Gastric Surgery Was a Push in Right Direction" - The Beet

Recommendation and review posted by Bethany Smith

Overview for Recombinant Protein Drug Market Helps in providing scope and definitions, Key Findings, Growth Drivers, and Various Dynamics.

The Recombinant Protein Drug market is expected to grow from USD X.X million in 2020 to USD X.X million by 2026, at a CAGR of X.X% during the forecast period. The global Recombinant Protein Drug market report is a comprehensive research that focuses on the overall consumption structure, development trends, sales models and sales of top countries in the global Recombinant Protein Drug market. The report focuses on well-known providers in the global Recombinant Protein Drug industry, market segments, competition, and the macro environment.

Under COVID-19 Outbreak, how the Recombinant Protein Drug Industry will develop is also analyzed in detail in Chapter 1.7 of the report., In Chapter 2.4, we analyzed industry trends in the context of COVID-19., In Chapter 3.5, we analyzed the impact of COVID-19 on the product industry chain based on the upstream and downstream markets., In Chapters 6 to 10 of the report, we analyze the impact of COVID-19 on various regions and major countries., In chapter 13.5, the impact of COVID-19 on the future development of the industry is pointed out.

A holistic study of the market is made by considering a variety of factors, from demographics conditions and business cycles in a particular country to market-specific microeconomic impacts. The study found the shift in market paradigms in terms of regional competitive advantage and the competitive landscape of major players.

Download PDF Sample of Recombinant Protein Drug Market report @ https://www.arcognizance.com/enquiry-sample/1241874

Key players in the global Recombinant Protein Drug market covered in Chapter 4:, Novo Nordisk, Changchun High & New Technology Industry, Merck Serono, Sanofi, Anhui Anke Biotechnology, GenSci, Roche, NCPC, Shenzhen Neptunus Interlong Bio-Technique, Heng Rui, Eli Lilly, Amgen, Pharmingen, SL PHARM, Kyowa Hakko Kirin, Ortho Biotech, Abcam, Livzon Pharmaceutical

In Chapter 11 and 13.3, on the basis of types, the Recombinant Protein Drug market from 2015 to 2026 is primarily split into:, Recombinant Insulin, Recombinant Human Interferon (rhIFN), Recombinant Human Erythropoietin (rhEPO), Recombinant Human Granulocyte Colony-stimulating Factor (rhG-CSF), Recombinant Human Growth Hormone (rhGH), Recombinant Human Follicle-stimulating Hormone (rhFSH), Others

In Chapter 12 and 13.4, on the basis of applications, the Recombinant Protein Drug market from 2015 to 2026 covers:, Hospital use, Clinic use, Household

[emailprotected] https://www.arcognizance.com/discount/1241874

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2026) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:, North America (Covered in Chapter 6 and 13), United States, Canada, Mexico, Europe (Covered in Chapter 7 and 13), Germany, UK, France, Italy, Spain, Russia, Others, Asia-Pacific (Covered in Chapter 8 and 13), China, Japan, South Korea, Australia, India, Southeast Asia, Others, Middle East and Africa (Covered in Chapter 9 and 13), Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Others, South America (Covered in Chapter 10 and 13), Brazil, Argentina, Columbia, Chile, Others

Years considered for this report:, Historical Years: 2015-2019, Base Year: 2019, Estimated Year: 2020, Forecast Period: 2020-2026

Some Point of Table of Content:

Chapter One: Report Overview

Chapter Two: Global Market Growth Trends

Chapter Three: Value Chain of Recombinant Protein Drug Market

Chapter Four: Players Profiles

Chapter Five: Global Recombinant Protein Drug Market Analysis by Regions

[emailprotected] https://www.arcognizance.com/purchase/1241874

Chapter Six: North America Recombinant Protein Drug Market Analysis by Countries

Chapter Seven: Europe Recombinant Protein Drug Market Analysis by Countries

Chapter Eight: Asia-Pacific Recombinant Protein Drug Market Analysis by Countries

Chapter Nine: Middle East and Africa Recombinant Protein Drug Market Analysis by Countries

Chapter Ten: South America Recombinant Protein Drug Market Analysis by Countries

Chapter Eleven: Global Recombinant Protein Drug Market Segment by Types

Chapter Twelve: Global Recombinant Protein Drug Market Segment by Applications12.1 Global Recombinant Protein Drug Sales, Revenue and Market Share by Applications (2015-2020)12.1.1 Global Recombinant Protein Drug Sales and Market Share by Applications (2015-2020)12.1.2 Global Recombinant Protein Drug Revenue and Market Share by Applications (2015-2020)12.2 Hospital use Sales, Revenue and Growth Rate (2015-2020)12.3 Clinic use Sales, Revenue and Growth Rate (2015-2020)12.4 Household Sales, Revenue and Growth Rate (2015-2020)

Chapter Thirteen: Recombinant Protein Drug Market Forecast by Regions (2020-2026) continue

List of tablesList of Tables and FiguresTable Global Recombinant Protein Drug Market Size Growth Rate by Type (2020-2026)Figure Global Recombinant Protein Drug Market Share by Type in 2019 & 2026Figure Recombinant Insulin FeaturesFigure Recombinant Human Interferon (rhIFN) FeaturesFigure Recombinant Human Erythropoietin (rhEPO) FeaturesFigure Recombinant Human Granulocyte Colony-stimulating Factor (rhG-CSF) FeaturesFigure Recombinant Human Growth Hormone (rhGH) FeaturesFigure Recombinant Human Follicle-stimulating Hormone (rhFSH) FeaturesFigure Others FeaturesTable Global Recombinant Protein Drug Market Size Growth by Application (2020-2026)Figure Global Recombinant Protein Drug Market Share by Application in 2019 & 2026Figure Hospital use DescriptionFigure Clinic use DescriptionFigure Household DescriptionFigure Global COVID-19 Status OverviewTable Influence of COVID-19 Outbreak on Recombinant Protein Drug Industry DevelopmentTable SWOT AnalysisFigure Porters Five Forces AnalysisFigure Global Recombinant Protein Drug Market Size and Growth Rate 2015-2026Table Industry NewsTable Industry PoliciesFigure Value Chain Status of Recombinant Protein DrugFigure Production Process of Recombinant Protein DrugFigure Manufacturing Cost Structure of Recombinant Protein DrugFigure Major Company Analysis (by Business Distribution Base, by Product Type)Table Downstream Major Customer Analysis (by Region)Table Novo Nordisk ProfileTable Novo Nordisk Production, Value, Price, Gross Margin 2015-2020Table Changchun High & New Technology Industry ProfileTable Changchun High & New Technology Industry Production, Value, Price, Gross Margin 2015-2020Table Merck Serono ProfileTable Merck Serono Production, Value, Price, Gross Margin 2015-2020Table Sanofi ProfileTable Sanofi Production, Value, Price, Gross Margin 2015-2020Table Anhui Anke Biotechnology ProfileTable Anhui Anke Biotechnology Production, Value, Price, Gross Margin 2015-2020Table GenSci ProfileTable GenSci Production, Value, Price, Gross Margin 2015-2020Table Roche ProfileTable Roche Production, Value, Price, Gross Margin 2015-2020Table NCPC ProfileTable NCPC Production, Value, Price, Gross Margin 2015-2020Table Shenzhen Neptunus Interlong Bio-Technique ProfileTable Shenzhen Neptunus Interlong Bio-Technique Production, Value, Price, Gross Margin 2015-2020Table Heng Rui ProfileTable Heng Rui Production, Value, Price, Gross Margin 2015-2020Table Eli Lilly ProfileTable Eli Lilly Production, Value, Price, Gross Margin 2015-2020Table Amgen ProfileTable Amgen Production, Value, Price, Gross Margin 2015-2020Table Pharmingen ProfileTable Pharmingen Production, Value, Price, Gross Margin 2015-2020Table SL PHARM ProfileTable SL PHARM Production, Value, Price, Gross Margin 2015-2020Table Kyowa Hakko Kirin ProfileTable Kyowa Hakko Kirin Production, Value, Price, Gross Margin 2015-2020Table Ortho Biotech ProfileTable Ortho Biotech Production, Value, Price, Gross Margin 2015-2020Table Abcam ProfileTable Abcam Production, Value, Price, Gross Margin 2015-2020Table Livzon Pharmaceutical ProfileTable Livzon Pharmaceutical Production, Value, Price, Gross Margin 2015-2020Figure Global Recombinant Protein Drug Sales and Growth Rate (2015-2020)Figure Global Recombinant Protein Drug Revenue ($) and Growth (2015-2020)Table Global Recombinant Protein Drug Sales by Regions (2015-2020)Table Global Recombinant Protein Drug Sales Market Share by Regions (2015-2020)Table Global Recombinant Protein Drug Revenue ($) by Regions (2015-2020)Table Global Recombinant Protein Drug Revenue Market Share by Regions (2015-2020)Table Global Recombinant Protein Drug Revenue Market Share by Regions in 2015Table Global Recombinant Protein Drug Revenue Market Share by Regions in 2019Figure North America Recombinant Protein Drug Sales and Growth Rate (2015-2020)Figure Europe Recombinant Protein Drug Sales and Growth Rate (2015-2020)Figure Asia-Pacific Recombinant Protein Drug Sales and Growth Rate (2015-2020)Figure Middle East and Africa Recombinant Protein Drug Sales and Growth Rate (2015-2020)Figure South America Recombinant Protein Drug Sales and Growth Rate (2015-2020)Figure North America Recombinant Protein Drug Revenue ($) and Growth (2015-2020)Table North America Recombinant Protein Drug Sales by Countries (2015-2020)Table North America Recombinant Protein Drug Sales Market Share by Countries (2015-2020)Figure North America Recombinant Protein Drug Sales Market Share by Countries in 2015Figure North America Recombinant Protein Drug Sales Market Share by Countries in 2019Table North America Recombinant Protein Drug Revenue ($) by Countries (2015-2020)Table North America Recombinant Protein Drug Revenue Market Share by Countries (2015-2020)Figure North America Recombinant Protein Drug Revenue Market Share by Countries in 2015Figure North America Recombinant Protein Drug Revenue Market Share by Countries in 2019Figure United States Recombinant Protein Drug Sales and Growth Rate (2015-2020)Figure Canada Recombinant Protein Drug Sales and Growth Rate (2015-2020)Figure Mexico Recombinant Protein Drug Sales and Growth (2015-2020)Figure Europe Recombinant Protein Drug Revenue ($) Growth (2015-2020)Table Europe Recombinant Protein Drug Sales by Countries (2015-2020)Table Europe Recombinant Protein Drug Sales Market Share by Countries (2015-2020)Figure Europe Recombinant Protein Drug Sales Market Share by Countries in 2015Figure Europe Recombinant Protein Drug Sales Market Share by Countries in 2019Table Europe Recombinant Protein Drug Revenue ($) by Countries (2015-2020)Table Europe Recombinant Protein Drug Revenue Market Share by Countries (2015-2020)Figure Europe Recombinant Protein Drug Revenue Market Share by Countries in 2015Figure Europe Recombinant Protein Drug Revenue Market Share by Countries in 2019Figure Germany Recombinant Protein Drug Sales and Growth Rate (2015-2020)Figure UK Recombinant Protein Drug Sales and Growth Rate (2015-2020)Figure France Recombinant Protein Drug Sales and Growth Rate (2015-2020)Figure Italy Recombinant Protein Drug Sales and Growth Rate (2015-2020)Figure Spain Recombinant Protein Drug Sales and Growth Rate (2015-2020)Figure Russia Recombinant Protein Drug Sales and Growth Rate (2015-2020)Figure Asia-Pacific Recombinant Protein Drug Revenue ($) and Growth (2015-2020)Table Asia-Pacific Recombinant Protein Drug Sales by Countries (2015-2020)Table Asia-Pacific Recombinant Protein Drug Sales Market Share by Countries (2015-2020)Figure Asia-Pacific Recombinant Protein Drug Sales Market Share by Countries in 2015Figure Asia-Pacific Recombinant Protein Drug Sales Market Share by Countries in 2019Table Asia-Pacific Recombinant Protein Drug Revenue ($) by Countries (2015-2020)Table Asia-Pacific Recombinant Protein Drug Revenue Market Share by Countries (2015-2020)Figure Asia-Pacific Recombinant Protein Drug Revenue Market Share by Countries in 2015Figure Asia-Pacific Recombinant Protein Drug Revenue Market Share by Countries in 2019Figure China Recombinant Protein Drug Sales and Growth Rate (2015-2020)Figure Japan Recombinant Protein Drug Sales and Growth Rate (2015-2020)Figure South Korea Recombinant Protein Drug Sales and Growth Rate (2015-2020)Figure Australia Recombinant Protein Drug Sales and Growth Rate (2015-2020)Figure India Recombinant Protein Drug Sales and Growth Rate (2015-2020)Figure Southeast Asia Recombinant Protein Drug Sales and Growth Rate (2015-2020)Figure Middle East and Africa Recombinant Protein Drug Revenue ($) and Growth (2015-2020)continue

If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:Analytical Research Cognizance (ARC)is a trusted hub for research reports that critically renders accurate and statistical data for your business growth. Our extensive database of examined market reports places us amongst the best industry report firms. Our professionally equipped team further strengthens ARCs potential.ARC works with the mission of creating a platform where marketers can have access to informative, latest and well researched reports. To achieve this aim our experts tactically scrutinize every report that comes under their eye.

Contact Us:Ranjeet DengaleDirector SalesAnalytical Research Cognizance+1 (646) 403-4695, +91 90967 44448Email: [emailprotected]

NOTE: Our report does take into account the impact of coronavirus pandemic and dedicates qualitative as well as quantitative sections of information within the report that emphasizes the impact of COVID-19.

As this pandemic is ongoing and leading to dynamic shifts in stocks and businesses worldwide, we take into account the current condition and forecast the market data taking into consideration the micro and macroeconomic factors that will be affected by the pandemic.

Here is the original post:
Impact Of Covid-19 on Recombinant Protein Drug Market 2020 Industry Challenges, Business Overview and Forecast Research Study 2026 - Scientect

Recommendation and review posted by Bethany Smith